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RECOMBINANT DNA AND THE REGULATION OF
BIOTECHNOLOGY: REFLECTIONS ON THE ASILOMAR
CONFERENCE, TEN YEARS AFTER
by
JOHN E. BARKSTROM'
The year 1985 marks the tenth anniversary of the International Con-
ference on Recombinant DNA Molecules held at the Asilomar Conference
Center, Pacific Grove, California in late February, 1975. The entire field of
genetic engineering technology or "gene splicing" is not much older than the
Conference itself. Many articles and much discussion have been occasioned by
the recombinant DNA debate, including legal symposia held by the Univer-
sities of Southern California and Toledo.' This article looks back at the events
which led to Asilomar, the debate which followed, and some of the legal and
ethical problems involved in the debate.
What is known today as genetic engineering really has no beginning apart
from previous biomedical research. However, if it were possible to pinpoint the
events which mark the birth of the technology, they would probably be certain
experiments carried on at Stanford University in the early 1970s. Researchers
in the departments of biochemistry and medicine were pursuing separate ave-
nues of research, yet these avenues would soon converge to produce a new
technology. The biochemistry department, focusing on an animal virus, some-
how stumbled on a method of slicing DNA so cleanly that it could re-form at
the cut and go on to infect cells. The medical department, focusing on bacteria
rather than viruses, developed a method of constructing a tiny molecular
messenger, capable not only of carrying a foreign "blueprint" into a bacterial
cell, but also of getting the bacteria to "read" and copy the tiny message.
Modern genetic engineering or gene splicing is full of unique terms.
Replicons, hosts, vectors, restriction enzymes, and plasmids are a few such
terms. However, in order to understand what went on at Stanford, only a few
very simple concepts need to be understood. In fact, only one concept is really
needed, the concept of how a bacterial "factory" turns itself on and off.
Whether a cell is dividing or producing a needed protein, there are on-switches
called "promotors" or "initiators" which start the process, and off-switches called
"terminators" which stop the process.'
*J.D. University of Kansas 1979; B.A. North Park College, formerly in the Manville Corporation litigation
section.
'See Biotechnology and the Law: Recombinant DNA and the Control of Scientific Research, 51 S. CAL. L.
REV. 964 (1978); Recombinant DNA Activities: International and Comparative Legal Ramifications, 12 U.
TOL. L. REV. 804 (198 1).
'The biochemistry of a cell is quite complex. However, in terms of labeling the major processes or cycles of a
cell, three parallel but separate terminologies are applied to the start-stop mechanisms. The three cellular
functions can be separated into: 1) cell division, 2) messenger RNA template formation, or the duplication of
DNA by RNA (transcription), and 3) the ribosomal synthesis of protein utilizing messenger RNA (transla-
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DNA forms the master blueprint of a cell. In order to facilitate production
of needed products, the cell makes templates of messenger RNA, (i.e., RNA
copies or duplicates of the DNA original). The messenger RNA is sent out into
the cell where ribosomes will attach to it. The messenger RNA is similar to a
railroad track. As a ribosome moves down this RNA track, it attracts and con-
nects molecules until it has constructed the trailing chain of molecules into a
protein. An "initiator sequence" tells the ribosome where the RNA track
begins and a "terminator" tells it where it ends.
Logic would suggest that the only on-off switches recognized by the
various parts or systems of a bacterium should be those of the bacterium.
However, this is not the case. Nature has provided some near-perfect im-
postors. Bacterial viruses, bacteriophages, contain molecular sites recognized
by bacterial components as valid promoter and initiator sequences. Thus,
when a bacteriophage injects its DNA (or RNA) into a bacterium, it can quick-
ly cause the bacterium to not only duplicate the viral DNA, but also to pro-
duce viral enzymes which will stop bacterial metabolism. So perfect are the
viral sites that bacteria produce new phage organisms until they fill up the
bacterial cell and burst or lyse the cell wall. As many as 20,000 phage per
bacterium can be produced before lysis.3
Another impostor is not as lethal as the bacteriophage. Small DNA
plasmids can fool bacteria with their on-off systems. Plasmids, many times
smaller than bacteria, are DNA 'particles' which reside inside bacterial cells.
Carrying only a few genes (or DNA sequences representing proteins), plasmids
nevertheless contain complete start-stop systems which can be utilized to con-
trol sophisticated chemical pathways. For example, once inside a cell, a single
plasmid can induce chemical changes to keep other plasmids of a similar group
tion).
I) Cell division
When a cell divides, the two DNA strands must separate and construct new strands of DNA, i.e., the
DNA chain must replicate itself before cell division takes place. The total unit or segment of DNA replica-
tion is called a "replicon." The starting point of replication is called the "origin of replication" and DNA
replication ends at the "terminus."
2) Transcription
When DNA in a cell "transcribes" its message unto a messenger RNA "template," i.e., creates an RNA
duplicate of itself, the beginning and end points form a "transcription unit." The start-switch, or beginning
point for the transcription unit is known as a "promoter" which itself contains an initial "startside" or "start-
point." The end-point is known as a "terminator."
3) Translation
The ribosomal "translation" of the messenger RNA template begins when ribosomes recognize an "ini-
tiation sequence" and ends when the ribosomes encounter the "terminator." "Elongation," the synthesis of a
protein chain by the ribosome, is a definitional description of what happens between the "initiator" and the
"terminator" sites.
See B. LEWIN. GENES. (1983). For DNA replication and the terms "replicon," "origin of replication" and
"terminus," see Id. at 503 and the Chapter 31 discussion following.
For RNA template formation during transcription and the terms "template," "transcription unit," "pro-
moter," "startpoint," and "terminator," see Id. at 76, 165-66, and 174.
For ribosomal translation and the terms "initiation sequence," "elongation," and "terminator," see Id. at
87-102 and 143-62.
'See C.K. MATHEWS. BACTERIOPHAGE BIOCHEMISTRY. 52-66, 100-187 (1971). For RNA phages see Id. at
288-310.
[Vol. 19: I
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from entering the cell. Plasmids have also been responsible for conferring
resistance to antibiotics on bacteria.
Plasmids and bacteriophages have, for millions of years, been performing
remarkable feats of genetic engineering on bacterial cells. They provide the
natural models on which modern genetic engineering is patterned. They have,
in fact, been more than models, for by incorporating segments of DNA into a
plasmid or phage itself, the natural control systems can be used directly to con-
trol the bacterial system.
Foreign DNA can be inserted into a bacterial cell. However, without a
promoter or initiator sequence familiar to the cell, the DNA is essentially ig-
nored and usually diluted out as the cell divides.' In 1971, researchers at Stan-
ford were researching the promoter/initiator sequence, when they developed
the idea of using a bacteriophage to carry a monkey virus known as simian
virus 40 or SV40 into an intestinal bacteria known as Escherechia Coli (E.
Coli). Unfortunately, the researchers had no idea what might result from the
experiment. The idea was mentioned to a cancer researcher, Robert Pollack, at
a summer workshop. Although Pollack did not know whether the experiment
would be successful, he did know SV40 could transform human cells in tissue
cultures into something that resembled tumor cells. Alarmed that the experi-
ment might prove too successful, resulting in a new and continuing source of
virus, Pollack called the head of the Stanford research team, Paul Berg. Berg,
after some discussion and thought, decided that the experiment might indeed
prove dangerous and temporarily shelved it.6 But, Berg and his team of re-
searchers had other work which would eventually prove as revolutionary in
practice as the SV40 experiment appeared in theory.
In order to produce a product such as insulin by using gene splicing tech-
niques, it is necessary to isolate those genes essential for insulin production. It
is important, therefore, to have a tool which can cut DNA in a very precise
and predictable manner. What is needed is a molecular scalpel. It was Berg's
team of researchers which uncovered the clues leading to the discovery of one
such molecular scalpel. While Berg had deferred the SV40 experiment, Berg's
lab continued to work with other aspects of SV40 research. In 1972, a
biochemist, Herbert Boyer, provided the Stanford lab with a bacterial enzyme
named Eco Ri. It was a form of enzyme called a "restriction enzyme."'
To understand the significance of Eco Ri, portions of the story of research
into the bacterial viruses known as bacteriophages mentioned above are
IM. ROGERS. BIOHAZARD. 40-41 (1977); LEWIN. supra note 2, at 224. For plasmid incompatibility see Id. at
518-20. For antibiotic resistance see Id. at 301-02.
IR.W. OLD & S.B. PRIMROSE, PRINCIPLES OF GENE MANIPULATION: AN INTRODUCTION To GENETIC
ENGINEERING, 4 (1981) Ihereinafter cited as OLD].
'ROGERS, supra note 4, at 35-38.
'
1 d. at 39.
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helpful. Most individuals are familiar with Alexander Fleming's discovery of
penicillin in 1928. Fleming noticed a mold had contaminated a bacterial
culture dish and had cleared a circular path free of bacteria in the immediate
vicinity of the mold.
The discovery of the bacteriophage in 1915 was a similar story. An En-
glish researcher, F.W. Twort, discovered that a bacterial culture had been in-
fected by something which killed the bacteria and turned the culture dish from
creamy white to near transparent. The "something" proved as effective at in-
fecting other cultures as it was lethal. Two years later, a French researcher, ob-
serving similar results, named the "something" bacteriophage - "eaters of
bacteria." Unlike penicillin, bacteriophage or simply "phage," did not work
well against bacteria inside the human body, and therefore research along such
lines was eventually abandoned. Research on the bacteriophage, however, con-
tinued.8
Eco Ri, the restriction enzyme which Herbert Boyer brought to the Stan-
ford labs, was the result of work in the field of phage research. It was a
bacterial enzyme, part of a bacterial defense mechanism utilized by bacteria to
defend against phage infection or attack. In 1952, it had been reported that cer-
tain phage strains had trouble killing bacteria. This phenomenon was called
"host-induced modification." Host-induced modification resulted when the in-
tended bacterial host released chemicals which could repel a phage attack.
Because the system restricted phage growth, this was also referred to as a
"restriction system."9 Out of an E. Coli restriction system, Boyer had isolated
the Eco R, restriction enzyme.
Restriction enzymes are an interesting set of chemicals. Although
bacteria are single-celled organisms, a bacterial restriction system parallels the
human body's immune system in its ability to recognize and degrade foreign
DNA. The 1952 results merely hinted at the diversity of systems and of the en-
zymes which compose these systems. Restriction enzymes do not react
chemically in the same way against foreign DNA. Some enzymes will attack
and cut both strands of the DNA double helix, others will cut one strand.
Other enzymes can travel along a DNA strand and cleave DNA at the specific
sites of a recognized chemical bond. Still other enzymes are not site-specific,
but will travel a measured distance along the DNA and cleave whatever is
positioned at that site."°
Eco R, exhibited several similar properties. It was a site-specific enzyme.
Another important trait was discovered when it was mixed with the SV40
virus in various 1973 experiments. It could cleave the SV40 DNA, but the
Vid. at 24-25.
'MATHEWS, supra note 3, at 124.
OOLD, supra note 5, at 12-14.
[Vol. 19:1
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cleavage site consisted of "sticky ends," or single strands of the DNA which
protruded or overlapped at the cleavage site. These "sticky ends" displayed a
strong molecular attraction for other such molecules coming in close proximity
to the sticky ends. To the surprise of the Stanford observers, even after SV40
had been cleaved by Eco Ri, it could recircularize or reform at the cleaved site
in a circular manner, and begin infecting cells as if nothing had happened."
The implications were astonishing. Since DNA strands are composed of essen-
tially only four types of molecules, an Eco R, enzyme could recognize and
cleave bonding sites on two entirely different DNA strands, which could be
combined utilizing the sticky ends at the cleavage sites.
Thus, the biochemistry department's contribution to genetic engineering
was the department's experimental observations of Eco R,'s cleavage of SV40.
The other contribution came from Stanford's medical department. A research-
er, Stanley Cohen, was studying plasmids. Plasmids are tiny particles of DNA
capable of directing the cellular activity of bacteria, in much the same manner
as bacterial viruses can direct such activity. Where Berg's group had supplied
the scalpel, Cohen's team provided the crucial on-off switch.
Cohen suspected that a plasmid could be used to carry foreign DNA into
bacteria. If a small DNA strand could be incorporated or "sewn" into a
plasmid's DNA, a bacterium might "read" the piggyback fragment as a valid
command of the plasmid itself. This theory proved correct. Incorporating
DNA from an African frog species into plasmid pSC101, Cohen, John Mor-
row, and Eco R, researcher Herbert Boyer observed that once inside an E. Coli
cell, the frog DNA was replicated by the host E. Coli cell. The plasmid on-off
switch actually worked. 2 The researchers were both ecstatic and alarmed.
They were alarmed not because it had been done, but because it had been done
with relative ease.
In June 1973, participants at the Gordon Conference on Nucleic Acids, in
New Hampshire, heard Herbert Boyer present the paper detailing the frog-
plasmid combination experiment. One participant commented after Boyer's
presentation: "Now we can put together any DNAs we want to."' 3 The remark
is said to have prompted the co-chairs of the conference, Maxine Singer of the
National Institutes of Health and Dieter Soil of Yale, to ask for a vote on the
safety of recombinant DNA work. Of the ninety-odd participants, seventy-
eight voted to send a letter of concern to the National Academy of Sciences. A
second vote decided on the publication of the letter.' The Asilomar Con-
ference became almost a foregone conclusion.
"ROGERS, supra note 4, at 39.
"Cohen, Chang, Boyer, Helling, Construction of Biologically Functional Bacterial Plasmids In Vitro, 70
PRoc. NATL ACAD. SC. USA 3240 (1973); See also Cohen, The Manipulation of Genes, 233 Sci. Am. 25-33
(July 1975); Cohen, Gene Manipulation, 294 N. ENG. J. MED. 883-889 (April 1976).
"RoGERS, supra note 4, at 42.
"Id. at 42.
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The "Singer-Soil" letter requested that the National Academy of Sciences
and the National Institute of Medicine appoint a committee to study the
hazards of recombinant DNA and to recommend specific action or guidelines
on its use. Since Paul Berg had been instrumental in the development of the
technology, had been involved in attempts to determine the ethical and safety
aspects, and was among the most knowledgeable in the field, he was requested
to advise the National Academy. Since his work had contributed to getting
the Academy into its unexpected predicament, perhaps his expertise could help
get it out.
Berg sought the advice of James Watson, the co-discoverer of the struc-
ture of DNA. At an informal meeting in late 1973, both agreed that a larger
group discussion would be helpful. In April 1974, that group, consisting of on-
ly ten researchers, decided that still another, larger meeting was necessary.
This meeting was tentatively set for February of 1975. However, more than
simply another round of meetings grew out of the discussion. Almost abruptly,
the group reached a concensus that many experiments might well be
dangerous and should be stopped. A decision was made to request, and even to
demand that certain experiments not be done, and that a temporary
moratorium be instituted on further research. 6 Calling themselves "The Com-
mittee on Recombinant DNA Molecules, Assembly of Life Sciences," the
group's members drafted a letter to Science magazine, setting forth their deci-
sion and the reasons for it. On July 18, 1974, a few days before the letter's
publication, Paul Berg, David Baltimore, and Richard Roblin held a press con-
ference to announce the moratorium and explain this letter. The letter not on-
ly publicized the moratorium, but also announced the February 1975 meeting
to be held at Asilomar.'7
Despite the initial fears raised by the specter of recombinant DNA work,
the final Asilomar invitation list numbered only 155; 83 U.S. participants from
research, government and industry, 51 participants from foreign countries,
and 21 news media and lay people." The proceedings themselves were not
unusual, considering the egos that are involved in any gathering of the top
minds in a field. Collateral issues often derailed discussion, each new working
group report produced heated argument, and debate covered everything from
the range of risk to the arrangement of sentences. Nevertheless, between the
Monday morning opening and the Thursday afternoon close, the participants
succeeded in reaching agreement on a draft of the "Statement of the Con-
"ld. at 43.
"Id. at 44-45.
"Some of These Artificial Recombinant DNA Molecules Could Prove Biologically Hazardous, NAT'L.
ACAD. OF Sci. NEWS REP., (Aug./Sept. 1974).
sSwazey, Sorenson, Wong; Risks and Benefits, Rights and Responsibilities: A History of the Recombinant
DNA Research Controversy, 51 S. CAL. L. REV. 1919, 1030 (1978) [hereinafter cited as Swazeyl.
[Vol. 19: i
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ference Proceedings" (Statement).9 While the Statement expressed caution and
provided some guidance for research, its central message was that the
moratorium could be lifted for all but the most dangerous experiments.
Therefore, work on recombinant DNA molecules could proceed with "ap-
propriate safeguards."' 0
Formalizing the results of Asilomar into actual guidelines for research
was left to a committee of the National Institutes of Health, which began its
task the day after the close of the Asilomar Conference.2' To the extent that
there would be any formal government involvement in the control of recombi-
nant DNA work, it would come in the form of the NIH Guidelines which were
finally released in the summer of 1976.22
THE LEGAL FRAMEWORK
In 1977, sixteen bills were introduced in Congress specifically aimed at
controlling recombinant DNA research, yet none passed. 3 Only seven or eight
such bills were introduced in the 1978-79 session of Congress. By 1980 this
number was reduced to one. The NIH Guidelines are virtually the only form
of government control for recombinant DNA research and even that control
focuses primarily on contracts involving government funding for research pro-
cured through the NIH.
This article will not discuss at great length the history of legislative or
regulatory control of recombinant DNA research. First, the subject has been
amply covered by past articles. Second, any discussion of legislation is largely
academic. Except for the now almost monthly press announcements of a new-
ly synthesized hormone or drug, most research goes largely unnoticed. A com-
bination of factors was probably responsible for the demise of legislative activi-
ty. The research is still viewed very favorably as a significant factor in the
ultimate conquest of disease, especially of cancer, and it takes a great deal of ef-
fort fueled by public outcry to push legislation through Congress. Further-
more, since no catastrophies have occurred, the concensus in the scientific
community is that it is safe.
As previously observed, the worldwide framework of control needed to
prevent such research is simply impractical. The research is neither com-
"'ROGERS. supra note 4, at 51-100.
mBerg, Baltimore, Brenner, Roblin Singer, Summary Statement of the Asilomar Conference on Recombi-
nant DNA Molecules, 72 PRoc. NArL. ACAD. SC. USA 1981 (1975).
2ROGERS, supra note 4, at 101-03.
"Recombinant DNA Research Guidelines 41 Fed. Reg. 27,902 (1976).
'
3Teichmann, Regulation of Recombinant DNA Research: A Comparative Study, 6 Loy. L.A. INT. & COMP.
L.J. I, 7 (1983); Recombinant DNA Technical Bull., Nov. 1978.
'Korwek, OSHA Regulation of Industrial Applications of Recombinant DNA Technology, 50 U. CIN. L.
REV. 284-85 (1981).
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plicated nor expensive, nor does it require elaborate laboratory equipment.
Because the techniques are so simple, it would be difficult to prevent even if
there was sufficient pressure for legislation, and, internationally, the concensus
is to push ahead as fast as possible."
Because NIH Guidelines provide a basic background, and because a good
portion of proposed legislation incorporated the Guidelines, the history of
legislation given here begins with the NIH Guidelines. The state laws and local
ordinances which have been enacted are discussed, not for their individual
significance, but for an understanding of Congressional efforts to pass "um-
brella" legislation. Finally, because of the resulting products or waste-by-
products involved, a brief overview or list of statutes which affect engineering
work is provided.
THE NIH GUIDELINES
The day after Asilomar, on February 28, 1975, when the NIH Advisory
Committee met to draft guidelines, it may or may not have sensed the coming
storm. Most of the biomedical research community was basking in the trium-
phant afterglow of the meeting. The Committee would probably later attest it
was "baking" in the intense "after coals." Initially this committee voted to
adopt the Asilomar guidelines until more extensive study could be conducted.
When the Committee drafted proposed guidelines, controversy stirred ap-
preciably. Meeting at Woods Hole, Massachusetts in July of 1975, the Com-
mittee essentially overrode a draft prepared by a subcommittee and, it was
charged, considerably weakened some recommended safety measures.26 Led by
Harvard Medical School's Richard Goldstein, forty-eight biologists petitioned
the NIH, complaining that the Committee's draft lowered "substantially" the
safety standards deemed necessary by the scientific community. 7
Extremely sensitive to the criticism, the Committee reviewed drafts of
three proposed guidelines, and from these developed a final proposed set of
guidelines. Finally, after public meetings and hearings, the formalized
Guidelines were issued on June 23, 1976.8 The Guidelines were a compromise
between the twin goals of promoting hoped-for research results and
eliminating potential hazards. As the Director of the NIH stated: "[Ojur prob-
lem then has been to construct guidelines that allow the promise of the
methodology to be realized while advocating the considerable caution that is
demanded by what we and others view as potential hazards." 9
"Fletcher, Ethics and Recombinant DNA Research, 51 S. CAL. L. REV. 1131-33 (1978).
'41 Fed. Reg. 27,903.
"Wade, Recombinant DNA: NIH Group Stirs Storm by Drafting Laxer Rules, 190 Scl. 767-68 (1975).
141 Fed. Reg. 27,903.
"Id. at 27,91 I.
[Vol. 19:1
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The Guidelines as formulated in 1976 can be divided into two areas, 1) ad-
ministrative and 2) technical or technological. The administrative can be
described as chain-of-command or committee-upon-committee. Each school or
other NIH-funded institution was responsible for the work of a "principal in-
vestigator," whose duties included evaluation of potential hazards, the choos-
ing of appropriate lab procedures, and the application for NIH approval. An
institution had to have a policy-setting and reviewing Institutional Biohazards
Committee (IBC). Also, the NIH had Initial Review Groups (Study Sections)
which reported ultimately to the NIH Recombinant DNA Molecule Program
Advisory Committee (RAC). Ultimately, the NIH could decide whether an ex-
periment would proceed or not."
On the technological side, the Guidelines required essentially that
"something" couldn't escape from the lab, but if it did, that it couldn't live for
long. The Guidelines set up a dual system of controls. First, physical contain-
ment or barriers would prevent the escape of microorganisms from the lab.
Second, biological controls would ensure the death of any organism which
escaped. There were four physical levels, from Pi, for experiments deemed of
"minimal" risk, to P4, for experiments designated "high" risk." The second
system of controls, biological, was divided into three levels, EK,, EK2, and
EK3. These three "host-vector systems" consisted of a "host," the cell in which
inserted DNA would be "grown" or would replicate, and a "vector," the DNA
carrier which could both carry DNA into a host cell and also switch on the
host cell's replication mechanism. Initially, a plasmid or a bacteriophage was
the usual vector. In the "host-vector" system the intent was that it would "self-
destruct." But, the E-K designation was somewhat inexact. An EK, label ap-
plied to then "presently available systems," while EK 3 was simply an EK2
system which had been "validated" by independent experiments in animals.
Since EK3 was to be the highest level of containment, no system could attain
that designation without NIH certification.32
The 1976 Guidelines took several pages to simply list the P and E-K
systems which were to be used in different types of experiments. Birds, for ex-
ample, required a P3 physical containment level in combination with an EK2
host-vector system.3 In some ways the 1976 Guidelines provide an historical
perspective and insight on the then current scientific assessment of the hazards
of DNA research. By June of 1983, when a subsequent set of new NIH
Guidelines were promulgated, the most dangerous experiments had to have
specific approval of the various advisory committees.-' However, in 1976 such
experiments had been absolutely forbidden. This class of experiments included
"Id. at 27,920-27.
111d. at 27,912-13.
"Id. at 27,915-17.
13d. at 27,917-20.
"4Guidelines for Research Involving Recombinant DNA Molecules, 48 Fed. Reg. 24556-57 (1983)..
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toxins such as botulism and diphtheria or insect and snake venoms. 35
It is the precautions for high risk, as assessed and contained in the 1976
Guidelines, which provide the imagination with the most interesting scenarios.
At the high risk P-4 level, a facility was to be engineered with "monolithic
walls," air locks, double-door autoclaves for the sterilization and removal of
waste, a separate negative pressure (inward) ventilation system, and Class III
Biological Safety Cabinets (enclosed cabinets with arm-length rubber gloves).'
From a technical standpoint the NIH Guidelines represented a "best-
guess" assessment of what experiments were dangerous and of what optimum
physical and biological means were available to control or eliminate the dan-
gers. From a legal standpoint, however, the Guidelines were quite weak, not
even achieving the status of a regulation. It was generally felt that the only le-
gal basis for enforcement arose from contract law." Institutions which re-
ceived funds from the NIH could lose such funds for violation of the Guide-
lines.' To provide a stronger contractual basis for the revocation of funds, the
NIH initially required a "Memorandum of Understanding and Agreement" to
be signed by an institution indicating, that it would abide by the Guidelines.39
With contract law providing the means of enforcing compliance, there
was a rather large loophole in enforcing the Guidelines. Individuals or orga-
nizations not dependent on the NIH for funding were not required to comply
with the Guidelines.1 From a comprehensive standpoint, the legal basis for the
Guidelines left many questions unanswered. In an attempt to remedy the situa-
tion, legislative bodies at the local, state, and federal levels became involved.
LOCAL AND STATE LAW
Recombinant DNA research provoked some very hot debate, particularly
in communities where large universities were set to begin work in the field. Ex-
cept for a brief mention of some highlights of local ordinances, the purpose of
bringing local laws into this discussion is primarily for background to Congres-
sional debate.
The city which spearheaded an intense though chaotic effort to halt DNA
research was Cambridge, Massachusetts. A June 8, 1976, article on
"Biohazard at Harvard," appeared in the Boston Phoenix. A few weeks later
311d. at 27,914-15. See also 45 Fed. Reg. 27384 (1980).
641 Fed. Reg. 27,913-27.
"See Korwek, The NIH Guidelines for Recombinant DNA Research and the Authority of FDA to Require
Compliance With the Guidelines 35 FOOD DRUG COSM. L.J. 633, 636 (1980).
3 1Cavalieri, Science as Technology, 51 S. CAL. L. REV. 1153, 1159 (1978) (such funding was $2.5 billion in
1977).
3941 Fed. Reg. 27,921. The "Memorandum" was eliminated by the November 1980 amendments to the
Guidelines.
1'See Berger, Corporate Responsibility for Recombinant DNA Activities. 12 U. TOL L. REV. 913, 916 (198 1).
[Vol. 19: I
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the Cambridge city council began holding public hearings," the first of which
culminated in a resolution by Mayor Alfred Vellucci to ban all recombinant
DNA research in Cambridge for two years. At a subsequent meeting the city
council voted down a two-year ban, but opted for a three-month moratorium.
Undaunted, Mayor Vellucci, at a meeting of the United States Conference of
Mayors, offered a different resolution prohibiting such research in any city un-
til a public hearing could be held.'
In terms of public debate, other communities followed the lead of Cam-
bridge. The cities of Ann Arbor, Michigan; Shrewsbury, Massachusets;
Princeton, New Jersey; Madison, Wisconsin; Bloomington, Indiana; and San
Diego, California were drawn into the controversy. Some cities only debated.
In others the debates resulted in legislation.'3 The states of New York and
Maryland also enacted legislation."
Whether a city council has the legal authority to regulate university
research is open to debate. Congress's concern over its preemptive powers, in
opposition to the application of widely varying local ordinances and state
statutes, became a key question in the Congressional debate.
FEDERAL LEGISLATION
If the Asilomar Conference is any indication, it could be said that the
biomedical research community is concerned about the prospect of federal in-
volvement in research.' By requiring substantial time and effort to obtain a
NIH grant, the research community was hopeful that its efforts at self-
regulation would stop or at least slow any new federal regulations.
Countless bills are introduced in Congress every year. However, many are
permanently lost in committee. For a bill to get serious consideration,
Representatives or Senators must perceive a strong public interest in a par-
ticular piece of legislation. By raising the issue of safety, calling for a
moratorium, and holding a meeting at Asilomar, scientists should have ex-
pected the introduction of at least one bill in Congress, simply because
legislators respond to media coverage, the media is perceived as a shaper of
public opinion and a barometer of its strength.
Writing legislation is an intense process which does not happen simply
because public pressure is increasing. If an existing law will suffice, Congress
can shift the focus of public pressure to enforcement agencies. When possible
'
1Gottleib, Biohazards at Harvard, Boston Phoenix, June 8, 1976, at 9, col. I.
42ROGERS, supra note 4, at 191-92.
"CAMBRIDGE, MASS., REV. ORD. ch. 1i, art. 1I, § 11-7 (1977); PRINCETON, N.J., REV. ORD. ch. 26A, §§ 1-13
(1978); AMHERST, MASS., BYLAWS Art. III, § 10 (1978); WALTHAM, MASS., REV. ORD. ch 22, §§ 22-1, 22-2
(1981); BERKELEY CAL., ORD. 500-N.S. (Oct. 21, 1977); EMERYVILLE, CAL., RESOLUTION 77-39 (April 1977).
"MD. PUB HEALTH CODE ANN. tit. 43, § 898 (1977); N.Y. PUB. HEALTH LAW tit. 32-A, § 3220 (McKinney
1978).
"1See ROGERS, supra note 4 at 50-100.
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laws were scrutinized in 1977, they were not encouraging to Congress. A com-
mittee composed of eighteen federal agencies, which looked into the ap-
plicability of existing laws to rDNA work, concluded that none of the existing
statutes completely answered the specific problems posed by recombinant
DNA research. Certain aspects of research did fall within the preview of ex-
isting statutes, but if challenged in court, agencies promulgating regulations
based on a broad interpretation of other statutes would have difficulty defend-
ing such regulations. The committee looked primarily at the Toxic Substances
Control Act, the Hazardous Materials Transportation Act, the Occupational
Safety and Health Act of 1970, and Section 361 of the Public Health Service
Act. After evaluating these statutes, the committee concluded a new law
would be needed to reach all aspects of the new biotechnology. '
As public opposition to research seemingly arose from nowhere in the
mid-1970's, scientists must have been a little daunted. Congress looked intent
on passing some form of new law. Nevertheless a scientific lobby was formed.
Harlyn Halvorson, a Brandeis University microbiologist who led the lobbying
effort, decided that the best tactic was not blind opposition to all legislation,
but selective support of the bill most favorable to the scientific community.,7
The bill chosen was H.R. 7897, introduced by Congressman Paul Rogers in
March 1977.48
Rogers' bill placed regulatory authority in the hands of the Secretary of
HEW, and required all federal agencies to comply with the NIH Guidelines.
Rogers' bill looked inviting when contrasted with the bill introduced by
Senator Edward Kennedy. While Rogers' bill allowed for local variation if
"special circumstances" or "need" existed, Kennedy's bill did not provide for
federal preemption. Local as well as federal control could exist even without
special circumstances."9 If localities merely required compliance with the NIH
Guidelines, this specter would not have seemed prohibitive. However, the ad-
dition of a myriad of local variations would have posed a serious problem.
Later in the year Senator Gaylord Nelson introduced a bill providing for
federal preemption. The bill, unlike Senator Kennedy's placed overall authori-
ty in the hands of HEW. Scientists urged support of Nelson's bill and eventual-
ly Kennedy announced he was withdrawing support for his own bill."
What may have turned the tide against federal legislation was simply the
4
'Interim Report of the Federal interagency Committee on Recombinant DNA Research: Suggested
Elements for Legislation, 2 (Mar. 15, 1977); Toxic Substances Control Act, 15 U.S.C. §§ 2601-2629 (1983);
Hazardous Materials Transportation Act, 49 U.S.C. §§ 1471, 1472, 1655, 1761, 1762, 1801-1812 (1983); Oc-
cupational Safety and Health Act of 1970, 29 U.S.C. §§ 651-78 (1985); Public Health Service Act, 42 U.S.C.
§ 264 (1983).
"Culliton, Recombinant DNA Bills Derailed: Congress Still Trying to Pass a Law, 199 Sci. 274.76 (1978).
4 Swazey, supra note 18 at 1069.
"Culliton, supra note 47, at 274-75.
"Id. at 276-77.
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passage of time, the accumulation of experimental data, a scientific reassess-
ment of the perceived risks, and a speech by Senator Adlai Stevenson III in
September 1977. Stevenson noted new developments indicating the safety of
rDNA research, pointed to the inadequacy of legislation hastily enacted, and
urged the Senate to delay action until more hearings could be held." It was
shortly after this speech that Kennedy announced the withdrawal of support
for his own bill. The fight in Congress for a new umbrella law was all but over.
PRESENT FEDERAL REGULATION
When courts have difficulty interpreting a statute, they will often turn to
the statute's legislative history for an indication of what the legislature intend-
ed. In the case of rDNA, the legislative history shows a clear intent by Con-
gress to not regulate rDNA research as a distinct technology. But the absence
of federal umbrella legislation does not provide rDNA work with a form of
blanket immunity from federal law. While Congress did not act to control
rDNA work, it also did not act to exempt it. No amendments were added to
health, safety, or environmental laws to lift regulation simply because of the
results that arose from rDNA research.
In general, any law relating to health or the environment will interface
with rDNA work at some point. The problem with applying the health and en-
vironmental statutes to rDNA technology was that most statutes required
some evidence of danger. Without some supporting evidence of a hazard, an
administrator would run afoul of the Administrative Procedure Act" and Due
Process considerations.
Furthermore, language in four of these acts is somewhat vague. The Tox-
ic Substances Control Act provides that the manufacture or use of a substance
can be prohibited if there is a "reasonable basis" for concluding that its
manufacture or use presents an "unreasonable risk" of injury to health or the
environment. 3 The Federal Food, Drug and Cosmetic Act prohibits the
adulteration of food and drugs. Adulterated food is defined as containing a
poisonous or "deleterious" substance. The FDA can also require compliance
with good manufacturing practices (GMP).-' Again, unless there is some fac-
tual basis for charging that rDNA produces a "deleterious" substance or that
rDNA manufacturing is not in conformance with good manufacturing prac-
tices, the FDA lacks a strong basis for regulation.
In 1978, Senators Edward Kennedy, Jacob Javits, Gaylord Nelson, Adlai
Stevenson, Harrison Williams, and Richard Schweiker, in a letter to the
Secretary of HEW, Joseph Califano, suggested that regulations governing
1 123 CoNG. REc. 15,411 (1977) (remarks of Sen. Stevenson); Culliton, supra note 47, at 277.
'5See 5 U.S.C. § 706(2)(c) (1983).
"15 U.S.C. § 2605(a) (1982).
-21 U.S.C. §§ 331, 342, and 351 (1972). See also Korwek, supra note 37, at 640.
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rDNA activities be promulgated based on Section 361 of the Public Health
Service Act. That section authorizes regulations "necessary to prevent the in-
troduction, transmission, or spread of communicable diseases." Secretary
Califano declined. Subsection (a) of Section 361 limits its application to human
beings. Secretary Califano noted that the Federal Interagency Committee on
Recombinant DNA Research had reviewed Section 361, and concluded that
application of it to rDNA research would rest on the "tenuous" conclusion
that products of all rDNA research caused or might cause human disease."
Finally, the Federal Insecticide, Fungicide, and Rodenticide Act allows
the EPA to refuse registration, a prerequisite to distribution or sale, only if
there are "unreasonable adverse effects" on the environment.56 All four of
these statutes provide some measure of control, but, absent any evidence of
danger inherent in rDNA techniques or technology, the threshold for regula-
tion is relatively high.
Because the ultimate aim of rDNA work is the production of a product, in
most cases, the end products will fall within some aspect of regulation. In addi-
tion to the four statutes mentioned, other laws may also come into play. The
laws include the Hazardous Materials Transporation Act," the Occupational
Safety and Health Act of 1970,58 the Clean Water Act,59 the Marine Protection
Research and Sanctuaries Act of 19 72 ,60 the Resource Conservation and
Recovery Act,6' the Safe Drinking Water Act,62 and the Federal Clean Air
Act.63 In addition, the Department of Agriculture has jurisdiction through four
acts: the Federal Meat Inspection Act,64 the Poultry Products Act,65 the Egg
Products Inspection Act," and the Virus, Serum and Toxin Act.67
The act with the most limited usage in terms of language has also had the
biggest impact. The National Environmental Policy Act (NEPA),61 which re-
quires only that an Environmental Impact Statement (EIS) be filed for federal-
ly funded research, was used successfully to prevent an experiment approved
5"42 U.S.C. § 264(a) (1976 & Supp. 111 1979). 43 Fed. Reg. 60,103-05 (1978).
567 U.S.C. § 136 a(c)(5)(c) (1983). For a good general discussion of laws applicable to rDNA work see T.
McGarity & Bayer, Federal Regulation of Emerging Genetic Technologies, 36 VAND. L. REV. 461 (1983).
5149 U.S.C. §§ 1801-12 (1983).
1-29 U.S.C. §§ 651-78 (1985).
5933 U.S.C. § 466-466g (1983).
- 16 U.S.C. §§ 1431-39 (1984).
042 U.S.C. §§ 6901-87 (1983).
642 U.S.C. §§ 300f-300 (1980).
6342 U.S.C. § 7401-7642 (1983).
421 U.S.C. §§ 601-95 (1984).
07 U.S.C. §§ 1621-30 (1985).
"21 U.S.C. §§ 1031-56 (1984).
621 U.S.C. §§ 151-58 (1984).
-42 U.S.C. §§ 4321-70 (1983).
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by the NIH.69
Two sidelights of these laws deserve passing mention. If any statute had
real potential for application to rDNA work from a language standpoint, it
would have been the Virus Serum and Toxin Act.70 Its language was almost
tailor-made for rDNA vectors. The Act forbids the preparation or shipment of
any worthless, contaminated, dangerous, or harmful virus, serum, toxin, or
analogous product. In the realm of possibility is the idea that a court might
agree that the splicing of a new gene into a virus vector constituted "con-
tamination." "Analogous product" could also apply to vectors, since they are
virus-like combinations. Unfortunately, the Act is limited in application since
it applies only to interstate, not intrastate production and, in addition, is
limited to the preparation of animal biologics (i.e. products intended for the
treatment of domestic animals).7
A second sidelight may be provided by the changes foreseeable in
biotechnology. Advances may provide federal agencies with problems relating
to the interpretation of statutory language. Federal meat inspection regula-
tions provide for the condemnation of carcasses and edible tissues which have
been rendered adulterated by the presence of biological residues.72 Advancing
biotechnology may pose an interesting problem. In a past experiment, growth
hormone in experimental mice reached a level eight hundred times greater
than normal.73 Will the genetically designed animal capable of "naturally" or
normally producing high levels of a substance be producing a "residue," and
will the animal's carcass be considered adulterated in such a case?
TORT LAW
Because there has been no new catastrophy on the order of the "Black
Death" as a result of rDNA work, the question of tort liability is largely
academic. Were such a catastrophic plague unleashed, the laboratory person-
nel might find a tort remedy a remote likelihood. An initial legal problem
might realistically involve a charge of murder. In terms of liability beyond
that, the options would be based on either negligence ' or strict liablity.75
The doctrines of negligence and strict liability as applied to rDNA
"Foundation On Economic Trends v. Heckler, 587 F. Supp. 753 (D.D.C. 1984).
"42 U.S.C. §§ 151-58 (1976).
"Grand Laboratories, Inc. v. Harris, 644 F.2d 729 (8th Cir. 1981) reh'ggranted, 660 F.2d 1288, cert. denied,
456 U.S. 927 (1982).
"See 9 C.F.R. §§ 301.2(zz), 309.16, and 311.39 (1985).
"Marx, Building Bigger Mice Through Gene Transfer, 218 Sci. 1298 (1982). See Jones, Genetic Engineering
in Domestic Food Animals: Legal and Regulatory Considerations; 38 FOOD DRUG COSM. L.J. 273, 280-82
(1983).
"See W. PROSSER. HANDBOOK OF THE LAW OF TORTS § 30 (4th ed. 197 1) (for a review of the elements of a
cause of action for negligence).
"See RESTATEMENT (SECOND) OF TORTS § 520 (1976) (for a review of the factors considered in a strict liabili-
ty suit).
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technology have been covered by other articles and will not be discussed here.76
Since, at present they are "future risks," they serve only as a reminder of what
may happen should something go wrong in the lab.
INTENTIONAL RELEASE EXPERIMENTS
On June 1, 1983, the NIH authorized the release of a form of genetically
engineered frost-inhibiting bacteria into a potato field. The bacteria act in such
a way as to prevent the formation of ice. A group of environmentalists, led by
author Jeremy Rifkin, filed suit for an injunction prohibiting the experiment.
Filed on September 14, 1983, in the District of Washington, D.C., the suit
charged that the NIH had violated the National Environmental Policy Act of
1969 and the Administrative Procedure Act. The basis of the suit was that the
NIH had failed to prepare an Environmental Impact Statement (EIS) and, in
addition, had failed to hold hearings prior to approval of the experiment. On
May 16, 1984, in a decision which stunned observers, Judge John Sirica
granted the injunction."
When the NIH released its initial set of Guidelines in 1976, included in its
list of "Forbidden Five" experiments, which were not to be performed at all,
was a prohibition against the "deliberate release into the environment of any
organism containing a recombinant DNA molecule. " " The prohibition on
such experiments was still in place when a revised set of Guidelines was pro-
mulgated in 1978. However, just underneath the list of prohibited experiments
was a new proviso: "[elxperiments in these categories may be excepted from
the prohibitions.., provided that these experiments are expressly approved by
the Director, NIH, with advice of the Recombinant DNA Advisory Commit-
tee ....
Without the one-line addition to the NIH Guidelines, Jeremy Rifkin
would have been unable to mount any significant challenge to the authority of
the NIH. Key to an understanding of the importance of that wording change is
"See generally Friedman, Health Hazards Associated with Recombinant DNA Technology: Should Con-
gress Impose Liability Without Fault, 51 S. CAL. L. REV. 1355 (1978); Karny, Regulation of Genetic
Engineering: Less Concern About Frankensteins but ime for Action on Commercial Production, 12 U.
TOL. L.R. 815, 853-57 (1981.
"Heckler, 587 F. Supp. at 75.3.
"41 Fed. Reg. 27,914-27,915.
The five types of experiments absolutely proscribed by the Guidelines were:
i) Cloning of rDNAs derived from certain pathogenic organisms, oncogenic viruses, or cells infected with
such agents;
ii) Deliberate formation of rDNAs containing genes for the biosynthesis of potent toxins (the prohibition
against botulinum or diphtheria);
iii) Deliberate creation from plant pathogens of rDNAs that were likely to increase virulence and range;
iv) Deliberate release into the environment of any organism containing a recombinant DNA molecule;
v) Transfer of a drug resistance trait to microorganisms not known to acquire such resistance naturally.
An additional classification, one with large-scale experiments, was prohibited unless it was of "direct
societal benefit."
"See Guidelines for Research Involving Recombinant DNA Molecules, 43 Fed. Reg. 60,108 Section I-D-6
(1978).
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that while it gives the NIH Director seemingly absolute power to deny permis-
sion for experimentation, the original language had not even conferred the
power to deny experimentation. Prior to the change, the NIH had no authority
whatsoever to oversee such experiments, no power to even consider such ex-
periments, let alone grant or deny permission to conduct them.
Any student of constitutional law knows that the President cannot,
without Congressional approval, simply declare and levy a tax. The Constitu-
tion confers on him no such authority. What the NIH did, by the addition of
that single sentence, was as revolutionary a concept as allowing the President
to singlehandedly levy a tax. One day the NIH had no control over deliberate
release experiments, the next day it had such power, and could deny or allow
experimentation on almost a whim.
In perspective the change was not spectacular. It did not, on a conceptual
level, approach the dimensions of a Presidential directive to levy a tax. Because
the Guidelines were based on contract law, a change in the Guidelines was no
more earth-shattering, legally, than a decision by Ford or General Motors to
change the terms of a contract by raising auto prices. Judge Sirica, in his deci-
sion to issue an injunction, did not even question the authority of the NIH to
make such a change. The basis for the injunction was, instead, the failure of
the NIH to prepare an Environmental Impact Statement assessing the impact
of the change. However, as Jeremy Rifkin observed after the decision was
handed down, whether the NIH was enjoined or not, private industry was not
under the legal constraints which NIH-funded institutions were, and was thus,
for the most part, unaffected by the ruling. °
The National Environmental Policy Act of 1969 (NEPA) requires that
federal decision makers compile an Environmental Impact Statement (EIS)
prior to final approval of all "major Federal actions significantly affecting the
quality of the human environment."" With that statutory command as a
guide, Judge Sirica had to determine first, whether NIH actions were "major
Federal actions" having a "significant effect" on the environment, thus requir-
ing an EIS. Second, if an EIS was required, what steps had been taken to com-
ply with that requirement. 2 Under the first prong of the statutory command,
Sirica determined that "major Federal action" was involved. On the question
of whether that action might have a "significant effect," Sirica found the NIH
had no information sufficient to make such a determination, either in the form
of a formal EIS, or in the form of an alternative "hard look" analysis." Finally,
since an EIS was necessary, Judge Sirica ruled that there were grounds for a
"15 Env't Rep. (BNA) 130 (May 25, 1984).
"National Environmental Policy Act of 1969 § 102(2)(C), 42 U.S.C. § 4332(A) (1983).
VHeckler, 587 F. Supp. at 761.
Old. at 762.
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finding of NEPA violations in the failure to prepare an EIS."
Judge Sirica determined that three allegations involving NEPA violations
by the NIH warranted serious analysis.' 5 An initial challenge was to the specif-
ic potato-field experiment approved by the NIH. A second, spin-off argument
related to the general issues involved in any intentional release experiment, or
a broad, programmatic assessment of the environmental problems involved.7
A third area addressed was that of changes in the text of the Guidelines."
Quite surprisingly, it was the seemingly innocuous language and text changes
which provoked the most intense scrutiny and the lengthiest analysis.
Because of the NIH's actions Judge Sirica determined that language
changes alone could place an agency within reach of NEPA's commands.
When the NIH promulgated the first set of Guidelines, it actually compiled
and adopted an Environmental Impact Statement, prompted by the belief that
the Guidelines themselves were a "major Federal action" having a potentially
significant effect on the environment. As stated by the Director of the NIH in
October 1977: "Itjhe issuance of Guidelines... with respect to recombinant
DNA experiments is viewed by NIH as within the category of a Federal action
that may significantly affect the quality of the human environment."' 9
Although Judge Sirica determined that the Guidelines and the actual deci-
sion to allow the potato-field experiment met the criteria for a "major Federal
action," Judge Sirica did not set out the specific criteria involved in a major ac-
tion. Instead, he pointed to statements emanating from the NIH. Judge Sirica
started with the premise that if the NIH in October 1977 had considered the is-
suance of the Guidelines to be a major Federal action, then a "major" change
in the original Guidelines would also constitute a major Federal action. ° Judge
Sirica reasoned further that if the NIH labeled an action or change as a
"major" one, then he would hold the NIH to that determination.9' Judge Sirica
thus pointed to a statement by the NIH characterizing a change in the
Guidelines as a "major" revision.92 The NIH Director had stated that granting
authority to permit deliberate release experiments was a "major" revision and
the actual decision a "major" one.9 Such statements were determined suffi-
cient to qualify the underlying action as a "major Federal action."
Id.
851d.
1Id.
"Id. at 761, 763.
"Id. at 761.
"See Id. at 758 (emphasis added) (quoting National Institutes of Health, Environmental Impact Statement
on NIH Guidelines for Research Involving Recombinant DNA Molecules of June 23, 1976).
lid. at 762.
91 Id.
'lid. at 760.
91d. at 759.
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Judge Sirica's arguments sound quite plausible. At the same time it may
be suggested that he is engaging in little more than a semantic game, because
what may be a major change in the text of the Guidelines, may or may not be
the equivalent of a "major Federal action." On the other hand, the point may
be well taken, that if the issuance of the original Guidelines did constitute a
"major Federal action" as the NIH assumed it did, then major changes of a
significant and substantive nature would quite appropriately be "major
Federal actions."
Having made a finding of major Federal action, Sirica then focused on the
second issue, whether such action was one "significantly affecting" the en-
vironment.' When the NIH did alter the Guidelines to permit intentional
release experiments, it prepared one environmental document. Although it
was not a full EIS, it was an environmental impact assessment (EA), which
assessment concluded that the Guidelines change would have no significant ef-
fect on the human environment."'
Despite this finding, Judge Sirica was apparently not reassured by the
government's analysis. What disturbed Judge Sirica about the EA was the fact
that it was almost totally lacking in either substantive analysis or in factual
data to analyze.'* There were, in fact, two EAs, although, as Judge Sirica
notes, the second was merely a summary of the first one.97 Absent from both
was any indication that the problems of intentional release had been addressed
at all, instead, the first EA postponed such analysis and referred in general
terms to NIH mechanisms for waiver decisions."
Judge Sirica's analysis of the EAs provided him with no concrete evidence
of any NIH deliberations. Nor was he reassured by the Director's refusal "to
articulate any standards, requirements, or values" to guide future decision
making." Just as disturbing was the fact that, after the 1978 revisions, the only
environmental documents which addressed intentional release experiments
were the notices of approval for three experiments."' Incredible as it seemed,
experiments considered too dangerous to allow in 1976, were matter-of-factly
given a go-ahead without any new data on their safety. "In 1978... the record
fails to reveal the Director of NIH, seeking, compiling, or addressing any
specific or general data about the environmental hazards associated with the
same type of experiments the Director had absolutely prohibited only two
years before on the grounds of environmental risk.""'
14d. at 762.
"Id. at 761.
%Id.
"Id. at 762.
ld. at 761.
"Id. at 762.
1Id at 760.
11id. at 763.
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There is an exception to NEPA's EIS requirements which allows an agen-
cy to forego an EIS if it has analyzed environmental problems against a stan-
dard comparable to that required by NEPA. That comparable standard re-
quires an in-depth substantive "hard look" at environmental problems. Unfor-
tunately, the NIH's review could not satisfy even one of the four "hard look"
criteria. The criteria require a court to inquire:
1) whether an agency took a 'hard look' at a problem;
2) whether the agency identified the relevant areas of environmental con-
cern;
3) as to the problems studied and identified, whether the agency made a
convincing case that the impact was insignificant; and
4) if there was impact of true significance, whether the agency convinc-
ingly established that changes in the project sufficiently reduced it to a
minimum."'
Since the NIH had barely looked at the problems, let alone taken a "hard
look," had overlooked rather than identified areas of concern, and had
presented no case on the insignificance of the environmental impact, Judge
Sirica's decision was a relatively simple one.
There were other reasons to be concerned with the NIH decision-making
process. It was as if the NIH had taken the attitude that it was in a position to
thumb its nose, both at the scientific ideal of experimentation and at the
legislative and judicial process.
Judge Sirica was no doubt surprised that the NIH could, on the one hand,
not articulate any standard governing the authorization of intentional release
experiments, while on the other hand, in effect, claim the benefit of the doubt,
that approval by the NIH of the three experiments meant a satisfaction of all
criteria under an unarticulated standard. It was not reassuring to hear the
Director's opinion that RAC review and public participation constituted an
adequate "standard." Failing to find any other evidence of the "standard"
governing the review process, Judge Sirica finally determined that:
On the basis of the Director's 1978 comments, therefore, the Court must
conclude that the "standard" for granting a waiver can only be described
as whatever it takes to win the confidence of, hopefully, at least a majori-
ty of the RAC and the subsequent approval of the Director of NIH.03
While the Director may have seemed eager to rely on the RAC in the mat-
ter of setting standards for actual experiments, there was a contrasting reluc-
tance to delegate the decision on whether to prepare an EIS. Somewhat puz-
zling is the complete about-face of the Director. Where the Director had been
keen on placing the burden for experimental release standards on the RAC,
there was a jealous guarding of the Director's asserted "case-by-case" decision-
1"Rld. at 757, 762.
'
31d. at 760.
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making powers in relation to the preparation of an EIS. The Director took
great pains to point out:
It is not the function of the RAC to determine what NEPA and the CEQ
[Council on Environmental Quality] regulations require. The RAC is not
constituted to interpret points of law and the requirements of NEPA.
Specifically, it is not a function of RAC to determine when an en-
vironmental assessment is required by NEPA.'1
''Id. at 760, citing 49 Fed. Reg. 697 (January 5, 1984). Judge Sirica interprets the Director's remarks to
mean that the Director distinguishes between the roles played by the Director and the RAC. The Director
thus delegates the scientific analysis of the actual release determination to a "standard" to be set in part by
the RAC. On the other hand, the Director reserves for his office a determination of when an EIS or EA must
be prepared.
A reading of the Director's comments in its full context suggests an alternative interpretation, namely
that, when the Director asserts that "lilt is not the function of the RAC to determine what NEPA and the
CEQ regulations require," the Director does not mean to distinguish between the role assigned to RAC and
the role assigned to the Director. In the beginning sentence of the same paragraph the statement is made
that "[tlhe NIH Recombinant DNA Advisory Committee [RACI does not have the responsibility to deter-
mine, and it is not appropriate for the NIH Guidelines to state what is, or is not, required by the National
Environmental Policy Act." (emphasis added).
The statement is made in the context of a request by Jeremy Rifkin, Edward L. Rogers and Michael W.
Fox that there be a more formal assessment of safety. The discussion does not distinguish between the role
to be played by the RAC and that to be played by the Director.
Judge Sirica may not have wanted to draw the conclusion that, on the one hand, when addressing critics
of NIH procedures, the Director would assert that the NIH, through the RAC, was not competent to make
a legal determination on the need for an EIS, while, on the other hand, asserting that the NIH was quite
competent to make such a determination in other situations on a case-by-case basis.
It would be the height of duplicity to even entertain such a notion, yet, based on the other actions of the
NIH, there is a sense that it has attempted to make both arguments at the same time: When addressing
Jeremy Rifkin, the RAC has no responsibility and is not constituted to interpret the law; when addressing
Judge Sirica, the NIH suddenly is competent to make a case-by-case determination based on unarticulated
standards.
The text of the NIH comments are presented here to give the full flavor of the context. The text is found
at 49 Fed. Reg. 696-97 (1984).
SUPPLEMENTARY INFORMATION: The National Institutes of Health will consider the following
actions under the Guidelines for Research Involving Recombinant DNA Molecules.
I. Proposed Amendments of the NIH Guidelines and Comments by the Director, NIAID.
A. Amendments Proposed by Messrs. Jeremy Rifkin and Edward Rogers.
Messrs. Jeremy Rifkin and Edward Lee Rogers, on behalf of the Foundation on Economic Trends,
Michael W. Fox, Environmental Action, Inc., and Environmental Task Force, in a letter dated November
7, 1983, propose the following amendments to the NIH Guidelines.
1. Amendment of the Section 111. The title of Section III of the Guidelines would be changed from "Con-
tainment Guidelines for Covered Experiments" to "Guidelines for Covered Experiments."
Messrs. Rifkin and Rogers argue that the current title of Section III reflects an orientation towards ex-
periments contained within a laboratory. However, the RAC is reviewing experiments involving the
deliberate release into the environment of certain organisms containing recombinant DNA. Messrs. Rifkin
and Rogers state that:
Accordingly, the focus should no longer be on the concept of containment alone, but rather on guidelines
to assure safety for all experiments, whether through containment procedures or other techniques.
2. Amendment of Section Ill-A. Section IlI-A would be amended by adding at the end thereof the follow-
ing paragraph:
A programmatic environmental impact statement (EIS) is required under the National Environmental
Policy ACT(NEPA), 42 U.S.C. § 4332, and the Council on Environmental Quality Regulations (CEQ Regs)
implementing NEPA, 40 CFR §§ 1502.1-1520.25, for the program involving deliberate releases into the en-
vironment of recombinant DNA molecules.
Messrs. Rifkin and Rogers, in their submission, provide a detailed explanation for this proposed modifica-
tion.
3. Additional Amendment of Section III-A. Section III-A would be further amended by adding after the
material set forth in the prior amendment the following paragraph:
Individual experiments involving deliberate releases into the environment of an organism containing
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Beginning with the claim that the NIH should make decisions regarding
the need for an EIS on a "case-by-case" basis, 05 there is a common thread run-
ning through NIH pronouncements. That common thread is "vagueness" and
a sense that the NIH is being evasive: waiver standards were "deferred;" a deci-
sion by the RAC was to be endowed with a presumption that it was made in
compliance with proper but unarticulated standards.
A glance at NIH pronouncements in the Federal Register suggests a cer-
tain laxness on the part of the NIH. A suggestion that NIH Guidelines be ap-
plied to NIH-supported research in foreign countries prompts the response that
a certificate of compliance with host country rules may be submitted in lieu of
compliance with NIH Guidelines, so long as safety practices of the two are
"reasonably consistent. '" ' 06 The NIH chooses to be diplomatic where it should
be rigorous. And when Jeremy Rifkin and Edward Rogers make the suggestion
that: "[wihere it is uncertain whether a particular experiment may or may not
have a significant impact on the environment, then, at the least, an en-
vironmental assessment (EA) must be prepared .. ,, "I The Director responds
by raising a legal, but inadequate, technicality that the RAC does not have the
responsibility to determine NEPA requirements. °8
recombinant DNA require the preparation of either an environmental impact statement or an environmen-
tal assessment.
In explanation of this proposed change, Messrs. Rifkin and Rogers state:
Where it is uncertain whether a particular experiment may or may not have a significant impact on the
environment, then, at the least, an environmental assessment (EA) must be prepared explaining the conclu-
sion reached on the question of the significant impact, and the relevant environmental agencies must be in-
volved in that assessment process. See CEQ Regs. §§ 1501.3, 1501.4, and 1508.9. At issue here are the great
variety of deliberate-release experiments that have potential environmental impacts.
B. Comments by the Director, National Institute of Allergy and Infectious Diseases, on the Amendments
Proposed by Messrs. Rifkin and Rogers.
The NIH Recombinant DNA Advisory Committee (RAC) does not have the responsibility to determine,
and it is not appropriate for the NIH Guidelines for Recombinant DNA Research to state, what is, or is not,
required by the National Environmental Policy Act (NEPA) (42 U.S.C. §§ 4321 etseq.) and the regulations
(40 CFR Part 1500) promulgated by the Council on Environmental Quality (CEQ) to assure the uniform im-
plementation of that Act. It is not the function of the RAC to determine what NEPA and the CEQ regula-
tions require. The RAC is not constituted to interpret points of law and the requirements of NEPA.
Specifically, it is not a function of RAC to determine when an environmental impact statement or an en-
vironmental assessment is required by NEPA. [In reading further, the Director, while stating that careful
consideration will be given to the potential environmental impact of waiver decisions, makes no distinction
between the role of the RAC and the role of the Director.)
It should also be noted that a proposal similar to that now proposed by Messrs. Rifkin and Rogers was
considered and rejected by the Director, NIH, at the time of the revision of the NIH Guidelines in December
1978. NIH Director Donald Fredrickson wrote in the Federal Register (43 FR 60083, December 22, 1978),
"Another commentator urged that for waiver of the prohibition of deliberate release into the environment,
the Guidelines explicitly require compliance with the National Environmental Policy Act (NEPA) and any
additional safeguards to be stipulated by EPA. Others urged that full Environmental Impact Statements be
filed on most exceptions to the prohibitions. As I noted in my Decision accompanying the PRG on July 28,
1978, all waiver decisions will include a careful consideration of the potential environmental impact. Some
decisions may be accompanied by a formal assessment or statement - a determination, however, that can
only be made on case-by-case basis." (Emphasis added).
01543 Fed. Reg. 60,083 (1978).
'043 Fed. Reg. 60,082 (1978).
1749 Fed. Reg. 695, 697 (1984).
"'Id. at 697.
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The arguments asserted on behalf of the NIH in Judge Sirica's court are a
little too pat and a little too convenient. An overly swift approval mechanism
for experiments, a lackadaisical attitude toward the need for experimental
data, and a general disregard for legal and administrative safeguards, make the
NIH look like a Barnum & Bailey promoter for the field of genetic engineering.
Insofar as the NIH was entrusted with the formulation of guidelines for
research, its role was intended to be that of a watchdog guardian. The NIH
understood that when it accepted that role. The fact is that society does not
need a watchdog agency looking out for the perceived interests of the business
and scientific communities. The business and scientific communities have
shown themselves quite capable of looking after their own interests.
The NIH disregarded the language and intent of the environmental laws,
approved an experiment in violation of those laws, and then attempted to de-
fend its actions by looking for a legal loophole. Such action was a sad combina-
tion of laziness and arrogance. At its best it was an example of a careless inat-
tention to detail and an inept disregard of procedural formalities. At its worst,
it is a disgraceful attempt to evade moral, ethical, and legal responsibilities.
In the abstract, spraying a few ounces or gallons of an ice-inhibiting
bacteria onto a potato field seems quite harmless. Based on the summary ap-
proval given the experiment by the NIH, it apparently agreed. But, there are
some not-so-imaginary horror stories in the ecological field which should snap
the scientific community back to reality. While it may seem trite, the local pet
shop can provide some frightening examples of just what can happen when
something new is introduced into the local ecological scene.
A trip to the local aquarium or pet shop will reveal any number of exotic
birds, fish, and animals - hardly a frightening menagery. In May 1967 a night
watchman at a Florida construction site, on hearing his dog bark, discovered
an albino catfish, which relentlessly marched toward the beam of light from his
flashlight. The problem was that the nearest waterway was half a mile away.
More perplexing, the native home of this walking catfish was southeast Asia
and eastern India. Imported to Florida in 1961, the fish have a voracious ap-
petite, will devour and eventually displace other fish in a pond, and are equipped
with a tremendous capacity for survival. These traits allow the catfish to
breathe directly with a lung if water disappears, and fast up to eight months if
food is scarce. After their discovery in May of 1967, more than 2500 albinos
were caught before August.09
The walking catfish is only one example of a species brought to a new
land and moving into the wild by escaping from captivity or being dumped in a
local river when the tourist went home. Also, South American piranha have
1"1L.J. MILNE & M. MILNE, ECOLOGY OUT OF JOINT - NEw ENVIRONMENTS AND WHY THEY HAPPEN 44-48
(1977) [hereinafter cited as MILNEJ.
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been caught in Florida waterways." '
The introduction of the large Cuban tree frog may have contributed to a
decrease in populations of native but smaller Florida frogs."' Another threat
posed to a Florida native is from Central America, the caiman. Nearly in-
distinguishable from alligators, caimans have been sold as "alligator" pet
substitutes and thousands have been released. And while humans fear alligator
attacks, alligators, in turn, fear caimans. Caimans unfortunately will not main-
tain the deep alligator holes which the native reptiles provide as a side benefit
for fish and fisherman.12
There are some major ecological disasters which have developed from
seemingly minor occurrences. In 1957, 26 African queen bees escaped from a
Brazilian research station. Mating with native bees, they produced offspring
which were aggressive, nomadic, and fast-breeding. Labeled "killer bees" for
good reason, at one point they fought a seven hour battle in one town against
Brazilian troops armed with flame throwers, hand grenades, and tear gas. They
have killed farmers and livestock, dive-bombed a funeral procession and, ad-
vancing 200 miles a year, may reach the U.S. by 1988. Mexican authorities
fear that when they reach Mexico by the summer of 1985, they may destroy
Mexico's honey industry."3
Eugene Scheifflin was a wealthy drug manufacturer who took an interest
in both Shakespeare and bird watching. Because he wished to see the birds
mentioned in Shakespeare's plays established in the New World, he released
forty pairs of European starlings in New York's Central park on March 6,
1890. Another forty pairs were released on April 25, 1891. All present starlings
in America are descendents of those released birds. The native American blue-
birds still left would not feel much gratitude toward Scheifflin since the aggres-
siveness of the starlings is focused on the nesting places of the smaller
bluebirds. "'
The introduction of the mosquito to Hawaii was responsible for the near-
extermination of a bird called the Hawaiian honeycreeper. There were no mos-
quitoes of any kind in Hawaii until 1826. Their mode of entry was a barrel of
water on the deck of a ship arriving from Mexico. These mosquitoes, infected
with bird malaria and pox, in turn infected the native honeycreepers with these
diseases. Because the mosquitoes found cool temperatures uninviting, only
those birds dwelling above three thousand feet survived."5
The NIH and many research scientists perhaps cry foul at Jeremy Rifkin's
"'0d. at 47.
'"Id. at 52-53.
"Id. at 238-39.
"'Chicago Tribune, December 26, 1984, p. 14.
'4MILNE. supra note 109, at 156, 220-2 1.
"id. at 244-46.
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suit. In perspective, the discussion surrounding the introduction of survivable
species into new environments was long overdue. It takes very little to upset
and destroy the fragile equilibrium of insulated biological worlds. The importa-
tion and release of threatening foreign animals and plants has, as often as not,
provoked not even a whimper. Unfortunately, Judge Sirica's ruling can be
neither expanded to cover such situations, nor made retroactive.
The arguments presented in the NIH lawsuit do not place the NIH in a fa-
vorable light. It appears not to have adequately studied the overall problem. A
workshop on DNA problems by the EPA in December 1983 indicates that that
agency, as well, may not be totally prepared to evaluate potential hazards.
Commenting on reports submitted for the workshop, a senior scientist stated:
A concern I didn't see addressed in these papers, and one that I believe
should be high on any list, is the potential for a genetically engineered
organism to out-compete native organisms and take over some en-
vironmental niche. This has happened numerous times with species in-
troduced from one part of the world to another."6
At least the EPA can be commended for its efforts to develop expertise in
the area. On the other hand, the NIH, as Judge Sirica infers in his opinion,
seems to have made no real attempt to determine if any hazards are involved in
new experiments.
A TEN YEAR PERSPECTIVE
Some three thousand years ago the prophet Nathan confronted David,
the King of Israel, over his actions in ordering the front-line death of a soldier
to cover up David's wrongdoing."7 That confrontation was an example of
what a constitutional law professor once called the indirect controls on govern-
mental power. A king, for all practical purposes beyond the law, was still sub-
ject to a commonly understood standard of conduct and could be called to ac-
count by higher authority when the standard was violated.
When the United States Constitution was written, it was decided that
direct controls were more effective at controlling the excesses of earthly rulers
than the moral tongue-lashings which the occasional Nathans could provide.
The newly independent colonists felt, as King George proved, that the poten-
tial excesses of a real king could in reality be quite excessive. For this reason,
the Constitution incorporated a system of checks and balances and the separa-
tion of powers.
Jeremy Rifkin and his cohorts at the Foundation for Economic Trends
could doubtless attest to the effectiveness of direct controls in comparison to
"'Memo of H.R. Brink, senior scientist, Exposure Assessment Branch, E.P.A. addressed to the participants
of the Biotechnology Workshop I, held in Washington, D.C., Dec. 14-16, 1983, at p. 10.
"'Samuel 2:1 1-12.
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that of indirect control, as shown by Rifkin's success in his suit with the NIH.
Until a federal court stepped in, the NIH was largely ignoring the moral lec-
tures which Rifkin unleashed from time to time.
What the law is and whether it was broken by the actions of the NIH, is a
question for the courts. But whether the NIH violated the standard it should
be adhering to is another matter. The medical community is revered because
its sacrifices and goals are still considered to be in service to humanity, as op-
posed to other groups which incidentally provide services and are considered to
be primarily out for profit. The medical community, in turn, holds the search
for empirical truth in high esteem, requiring the truth of a given proposition to
be proven by empirical evidence. What came out in the NIH suit points to an
unsettling suspicion, namely that without empirical evidence to support its
decision the NIH nevertheless chose to proceed with experimentation.
A decision to go forward, without supporting evidence, would seem a bla-
tant violation of the scientist's code. There is, thus, a violation on the scientific
side. On the legal side, the NIH chose to run interference directly over
whatever rules stood in the way of its decision. In short, the NIH is displaying
symptoms of a single-minded determination to proceed with rDNA experimen-
tation at all costs, be those costs in ethical, scientific, or procedural terms.
Laws can be evaded and goals can be achieved by sheer political power.
The question which needs to be addressed, however, is whether the ultimate
goal is set high enough to justify any means employed in attaining it. Pressure
to forge ahead with research is coming from companies who may not survive
financially for much longer. Because laws are usually intended to serve a more
lasting purpose and not some immediate very short-term goal, the question is
whether the NIH should proceed, based on these immediate concerns.
What appears to be afflicting a part of the scientific community is a single-
minded focus on curing disease, but a somewhat blurred or abstract perception
of human life. Curing disease is not necessarily the same thing as saving a life.
Many diseases can be cured, but with drugs which will exact a fatal price for
their saving powers.
With fame and fortune riding on the discovery of a cancer cure, scientists
at Asilomar, with a competitive intensity, were anxious to get on with the
research. Curing cancer or disease became not a means of overcoming human
tragedy, but simply a more complex puzzle to be solved, representing an in-
teresting and overriding goal, or a trophy symbolizing success. Whether injury
or death might result from a laboratory accident, and whether legislation or
regulation might cut down on such chances, became of secondary importance
to that all-consuming passion of curing cancer. James Watson no doubt ex-
pressed the feelings of many when he commented: "[wle can just suffer the
possibility that someone will sue us for a million dollars if things don't work
[Vol. ! 9: I
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out.""' And while scientists have downgraded the assessment of risk associated
with rDNA research, Watson's statement is a rather understated euphemism
for the results of an "experiment gone bad." The estimated 17 to 28 million
fatalities associated with a four year visitation by the Black Death in the four-
teenth century demonstrates what happens "if things don't work out," as does
the 15 to 25 million victims of the world flu epidemic of 1918-1919.119
ACADEMIC FREEDOM
Sooner or later, in reading through the articles written on Asilomar and
the rDNA debate, one is likely to come across references to Galileo. Govern-
ment attempts to regulate research are compared to the Inquisition's treatment
of Galileo, who was forced by the Inquisition to recant his theory that the
earth was not the center of the universe. The analogy appears so often as to be
almost a knee-jerk response set off by a hair-trigger sensitivity. So often is it used
that there is a temptation to ask, not when was it that the Church abolished
the Inquisition, but how soon can the Inquisition be brought back?
It is not the purpose of this article to mount a full-scale philosophical at-
tack or defense on academic freedom, save for a few comments on certain
aspects of the debate. The concept of academic freedom was established
because societies have learned that "advances in civilization" have come when
ideas are given a free reign. Like freedom of religion, it has been felt that more
good will come out of a situation in which government does not meddle.
Nevertheless, academic freedom is society's gift to the world of science, not the
researcher's private kingdom. It is not an absolute inviolate right granted to
scientists at birth, nor is it the paramount goal of society.
Scientists are best equipped to develop arguments for scientific freedom,
but it must be remembered that academic freedom is but one of a number of
areas competing for the attention of the collective community we call society.
Newsmen will contend that freedom of the press is just as important a "foun-
dation" of freedom as academic inquiry. Civil libertarians will contend as
strongly that the constitutional rights of accused persons are a similar cor-
nerstone. In the end, when these competing interests confront each other,
society will be the ultimate arbitrator. Courts have been willing to let reporters
sit in jail when criminal defendants seek a witness buried in the reporter's con-
fidential notes. And those who contend that the tail of academic freedom
should wag the dog, might take cognizance of the fact that political pressure to
protect the "rights of law-abiding citizens" is forcing a retreat by those civil
libertarians asserting the "rights of criminals."
A second point about the debate is that there are places and times when
"'ROGERS, supra note 4, at 64.
1"R.S. GOTTFRIED. THE BLACK DEATH NATURAL AND HUMAN DISASTER IN MEDIEVAL EUROPE, 77 (1983);
see also R. HARE. M.D., POMP AND PESTILENCE - INFECTIOUS DISEASE, ITS ORIGINS AND CONQUEST. 91
(1955); W.I.B. BEVERIDGE, INFLUENZA, THE LAST GREAT PLAGUE (1977).
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an argument is simply inappropriate. The actions of a control tower at a major
airport in directing airplanes in when to take off and land can be labeled as a
restriction on the individual freedom of a pilot to do as he pleases, however,
such an argument lacks even the slightest degree of credibility. The use of
Galileo as an example may not be a particularly appropriate one for the
biological sciences. Galileo's writings involved highly theoretical interactions
of distant planets, stars and galaxies, not the more immediate physical dangers
of experimentation with thermonuclear detonators or the plague bacillus.
From time immemorial, and long before academic freedom of inquiry gelled in-
to a principle, governmental authorities have been responsible for the quaran-
tine of disease-bearing ships and the control of the spread of contagion.
Those who choose to, in Robert Sinsheimer's words, "wave the flag of
Galileo"'20 at every opportunity, at the least appear to be crying wolf a little too
often. While scientific writing demands putting one's best foot forward, exag-
gerated and untrue comparisons to Galileo seem out of place in the context of
the scientific ideal of empirical truth. On a more concrete level the argument
becomes almost obscene. American scientists are becoming millionaires on the
strength of their expertise while Andrei Sakharov, the Russian physicist, is be-
ing tortured on the strength of his beliefs.
In perspective, the issue of academic freedom will largely remain a
tempest in a teapot. The likelihood of governmental interference in scientific
inquiry is remote, not so much because the scientific community opposes it,
but simply because society does not demand it. A request to Congress endorsed
by Jerry Falwell, asking for a ban on certain experiments, is unlikely to gain
much support.' At the same time, the reality is that a lay jury would find
heavy liability by delicately, but decisively, cleaving the line which separates
negligent experimentation from that of true academic inquiry. The parameters
of the debate were summarized by Professor Capron - just as "the image of a
broken Galileo recanting his 'heresies' haunts any discussion of controlling
basic research," so also "direct risks of physical injury" have provided a "tradi-
tional basis for injunction and damages." ' In practical terms, the decision to
go forward with research, as evidenced by Congress' refusal to legislatively
control it, is a societal concession to those who hold the view that real risks are
quite small, the potential dangers speculative and the benefits adequate on the
risk/benefit scale.23
In terms of the presentation of arguments, those who call on Galileo's im-
'2'Sinshimer, Troubled Dawn for Genetic Engineering, New Scientist, Oct. 16, 1975, at 148.
21 See MARSHALL, The Prophet Jeremy - Thou Shalt Not Splice Genes, The New Republic, Dec. 10, 1984
at 20.
12Capron, Prologue: Why Recombinant DNA?. 51 S. CAL. L. REV. 973, 978 (1978).
"'
3See Fletcher, Ethics and Recombinant DNA Research, 51 S. CAL. L. REV. 1131, 1136-37 (1978);
Englehardt, Jr., Taking Risks: Some Background Issues in the Debate Concerning Recombinant DNA
Research, 51 S. CAL. L. REV. 1141 (1978).
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age at the slightest whisper do a great disservice to their cause. Galileo does not
translate well when the debate turns to actual risks involved in experimenta-
tion. Galileo is most forceful when the argument is regulation of ideological in-
quiry, but is a very weak analogy on disease risks. In any debate, one has to
watch proponents of academic inquiry, for they can subtly pull any argument
concerning health regulations over to ideological ground, where Galileo's
reputation and persecution provide a stronger argument.
Perhaps the best presentation of the argument was made by Professor
Carl Cohen of the University of Michigan. Professor Cohen, conceding that
academic freedom is not totally immune from regulation, noted that "Itihose
who argue, as I do, that the commitment to free inquiry is critical to the place-
ment of the burden of proof, do not contend that never, under any cir-
cumstances, may restrictions upon inquiry be imposed."' 24 Professor Cohen ex-
panded on his perception of the freedom granted, claiming "[academic
freedom] is not an enforceable claim against the assets of others. Freedom of
inquiry is not a right in the strong sense that the scholar or scientist can de-
mand the provision of means needed to pursue the particular line of research
he thinks wise. .... ,,
While the scholar is expected to experiment and test:
This does not mean, obviously, that the professional investigator is free
from all restraints, that academic freedom is an absolute. Institutions may
and do formulate rules for the guidance of research within their precincts.
Medical experimentation with human subjects, an invaluable instrument
for the achievement of humane and scholarly objectives, is yet properly
subject to carefully formulated restrictions. 26
The development of legal and governmental systems has been a matter of
trial and error. The jury system was instituted because it was felt that there
were significant problems with the system of trial by ordeal. Similarly, the
legislative branch of government and the procedural formalities incorporated
into the judicial and administrative processes, whereby laws are made and in-
terpreted, was a considered response to past defects.
If this article takes a critical view of the workings of the NIH decision-
making process and a cautious approach to rDNA research, perhaps it is
because of past history. Anyone who takes statements at face value in the
business world will not survive long. And it is not always safe to rely solely on
the expertise of experts. As some major accounting firms have discovered,
escaping liability can depend on treating the assertions of corporate officials
with some degree of skepticism.
'
2 Cohen, Restriction of Research with Recombinant DNA: The Dangers of Inquiry and the Burden of Pro-
of 51 S. CAL. L. REV. 1081, 1102 (1978).
11d. at 1106.
06Id. at 1107.
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The NIH was entrusted with the regulation of rDNA research because it
was presumed to have the most expertise in the field. It was entrusted with the
responsibility for decision making because its scientists can develop and inter-
pret biological evidence, not because the NIH has a special ability to make
decisions in the absence of supporting evidence. Anyone is capable of making a
simple yes or no decision and any federal agency could have decided to go
ahead with the potato patch experiment by flipping a coin. To analogize, the
Securities and Exchange Commission might have required a more thorough
environmental impact study through its financial disclosure requirements than
the NIH undertook. Conferring an advanced degree is presumed to confer
some level of competence in a field. However, officials at the NIH are not paid
simply to rubber stamp a decision based on no more than the collective
authority of a committee of degreed individuals. A basic mastery of a subject
matter is no substitute for a specific study of a particular problem.
LESSONS FROM THE PAST AND DEJA Vu
The medical field has made some of its greatest advances by a meticulous
attention to detail and a careful study of medical case histories. If there is one
thing missing in the rDNA debate, it is perhaps a sense of the past. So con-
vinced were scientists and reporters of the potential dangers from a future
doomsday bug that the enormity of past plagues and epidemics was largely
lost. So certain were researchers of this new tool that a good deal of caution
was thrown to the wind, not in terms of laboratory procedures or safety, but in
terms of knowledge. If there is one lesson which should be taken to heart from
the past, it is that it is dangerous to base assumptions and make pro-
nouncements based on knowledge which is not complete. Of course it is
somewhat difficult to know what one does not know. On the other hand there
is a sense of overconfidence, even cockiness, of which the willingness of the
NIH to dispense with experimental evidence is probably symptomatic. We
know a good deal more than medical experts of a hundred years ago, but we
are still only "on the verge of" a cancer cure. The ever present danger is in suc-
cumbing to a false belief that, through the illusion of certainty, this time we
have an answer and this time we really are unique. The NIH was certain that
it now knows enough to dispense with experiments, and on the legal side, to
dispense with past procedure. The question which should be asked, however, is
whether there is now any particularly pressing reason, experimentally or legal-
ly, to cut down all the laws simply to get at the Devil.
Deja vu is the phrase used when there is a sense that one is previewing a
past event in the present. It may have more relevance than is at once apparent,
for we have been here before.
Lung cancer is a disease familiar to nearly everyone. Mesothelioma, how-
ever, is a disease which is part of the vocabulary of a much smaller group of in-
dividuals, those familiar with the medical and legal aspects of asbestos. Meso-
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thelioma is also a cancer, but of the lining surrounding the lungs. Unlike lung
cancer, a diagnosis of mesothelioma is a certain death sentence, death often
coming between six to eight weeks after diagnosis. Mesothelioma is one of sev-
eral diseases which have caused the filing of 20,000 lawsuits against the Man-
ville Corporation, with a potential total liability estimated to be $2.5 billion.' 27
The safe threshold level of exposure to asbestos while avoiding
mesothelioma is not known. A summer's work exposure can be sufficient. But
the time between initial exposure and development of the disease can be as
long as ten, fifteen, twenty, even forty years. It was not until 1964 that the
evidence was considered strong enough to definitively state that there was a
connection between asbestos exposure and the disease.'28 It has been asserted
that nothing has gone wrong in research involving rDNA and that it appears
to be safe. Yet with the field barely ten years old, the question presented is how
scientists can be certain. There are many "conventional" diseases with long
latency periods besides mesothelioma. Although D.E.S. had been prescribed as
early as 1947, cancer did not show up in children born to women who were
given D.E.S. until 1971.119 Veterans exposed to Agent Orange in Viet Nam
often did not develop symptoms until years later. 3 ° Whether an accurate obser-
vation, the rabies virus has been recorded as having, in a few cases, an incuba-
tion period of a year.'
Fear of the release of a doomsday bug through rDNA research has largely
subsided. Yet, as mentioned previously, the Black Death of 1347 through 1351
killed an estimated twenty-eight million. It began in October, 1347, when a
Genoese fleet with its sick crew sailed into the Sicilian harbor of Messina. 132
Another 'doomsday bug' was unleashed on the New World by the Spaniards in
the early 1500s in the form of smallpox. Estimates of the number who died
range from a low of two million to a high of fifteen million, and all in a period
of less than six months.33
It was Cotton Mather who introduced smallpox innoculation to the New
World in 1721. That innoculation was not without controversy. Indeed, it was
opposed by some as shown by the fact that, although it failed to explode, some-
one had a homemade grenade thrown into Mather's house. 34 Smallpox vac-
cination no doubt saved many lives, but it could be dangerous in some cir-
2 Manville: A drama with no end in sight. The Denver Post, August 26, 1984, at J12.
"'Selikoff, Churg & Hammond, Asbestos Exposure and Neoplasia. 188 J. AM. MED. ASsoc. 22 (1964).
"Downey, Theories of Recovery for DES Damage. Is Tort Liability the Answer? 4 J. LEGAL MED. 167
(1983).
'"Podgers, Toxic Time Bombs - Say Latent Disease Suits Will be Key Battleground in '80s. 67 A.B.A.J.
139 (1981).
"'A. CHASE. MAGIC SHOTS - A HUMAN AND SCIENTIFIC ACCOUNT OF THE LONG AND CONTINUING STRUG.
GLE TO ERADICATE INFECTIOUS DISEASES BY VACCINATION. 134 (1982).
"GOTTFRIED, supra note 119 at iii.
"'D.R. HOPKINS. PRINCES AND PEASANTS- SMALLPOX IN HISTORY. 207 (1983).
1'4d. at 248-50.
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cumstances. In the eighteen hundreds, sixty-three children at Rivalta, Italy
were vaccinated from a faccinal pustule of an apparently healthy baby. Unfor-
tunately the donor baby had syphilis, and forty-four of those vaccinated
developed syphilis; several died and some infected their mothers and nurses.
3
It was a rare hazard of innoculation, but was the result of the incomplete
knowledge of disease transmission. In 1767, a London physician innoculated
himself deliberately with gonorrhea, but unknowingly, with syphilis as well. 36
Those who led the way, like Koch and Pasteur, and those who followed,
became known as microbe-hunters. They had some brilliant successes, received
public accolades, government appointments, but also encountered failure.
Then, as now, there were high expectations for the new medical discoveries.
The theory was that fitting the pieces together in an understanding of the low-
ly germ was the solution to all medical problems. It is with those researchers of
the late nineteenth century that one gets the sense of having been here before.
Robert Koch first came to the attention of the medical world in 1876
when he demonstrated the ability of the anthrax bacillus to form spores and
still remain infectious. In 1880 Koch was made Extraordinary Associate of the
Imperial Health Office. In 1882 Koch presented a paper on the isolation of the
bacillus of tuberculosis.'37 Louis Pasteur worked for years analyzing problems
of the French breweries and distillers. In 1880 while experimenting with
chickens he discovered that an injection of weakened chicken cholera con-
ferred immunity. In June 1881 he demonstrated a successful anthrax vaccine
and in July of 1885, he began injections of a rabies vaccine on a small boy bit-
ten by a rabid dog. 3 ' That vaccine was an astonishing achievement considering
the fact that the agent of rabies was a virus much smaller than any of the
microbes Pasteur had previously encountered.
There were other successes as well. Diptheria antitoxin was successfully
tested in the 1890s. The discovery that the tsetse fly carried sleeping sickness
and that mosquitoes carried malaria, led not to vaccines, but to preventive
measures which effectively reduced contagion.
Just as twentieth century researchers would later refine disease-fighting
techniques and discover important cures and preventive measures, researchers
of the nineteenth century also made startling advances. But there were also
some terrible failures. What is more than a little disturbing is that some of the
symptoms displayed by the scientific community of today appeared a hundred
years ago. Newspapers, then as now, trumpeted new triumphs, and the scien-
tific community then as now, engaged in a fierce and nationalistic competition
"lid. at 85.
01d. at 410.
'P. DE KRUIF. MICROBE HUNTERS. 113-15, 117, 129-30 (1959).
"lid. at 143, 150-153, 170.
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to discover, first, the microbe, then the cure. At stake were honors, positions,
and national pride.
In an article entitled Science as Technology, L.F. Cavalieri recounts the
story of the announcement of the synthesis of somatostatin. On November 2,
1977, Dr. Philip Handler, president of the National Academy of Sciences, was
testifying before a Senate Subcommittee holding hearings on rDNA
technology. During the course of that testimony, Dr. Handler announced that
a team of researchers had succeeded in its efforts to synthesize the chemical
somatostatin. According to Professor Cavalieri, one of the canons of scientific
propriety in the medical research area is the scrutiny of works prior to publica-
tion. Therefore, Dr. Handler's announcement, before submission of a
manuscript on the research, was an unheard-of breach of the scientific canons.
Compounding Dr. Handler's breach was a decision by Science magazine not to
call for or publish the collective letters critical of such conduct. 3
Professor Cavalieri makes the point that technology does not really fall
within the protection of academic freedom. "[Tihe synthesis of somatostatin is
a technological act that, unlike the practice of pure science, has no claim to
freedom of inquiry.""' Furthermore, incorporating the competitive spirit on
the intense level of industrial rDNA work does not encourage the free ex-
change of ideas, and in fact fosters secrecy and noncommunication. 4' These
are undesirable traits in a field devoted to the expansion of human knowledge.
The article decries the use of science as a competitive game.
[Science is treated] . . . as a bona fide tournament. This is regrettable
because it tends to legitimize this sort of fierce rivalry and makes it appear
as simplistic competition which it is not; hasty results, cut-corners in safe-
ty procedures, excessive personnel, secrecy, and so forth are all part of this
unseemly game .... "
On May 31, 1881, Louis Pasteur watched as a fatal dose of anthrax was
administered to a group of sixty animals. Some two weeks before, Pasteur had
injected twenty-four out of the group with his newly developed anthrax vac-
cine. On June 2, 1881, Pasteur watched triumphantly as the unvaccinated ani-
mals all died while not one of those vaccinated showed signs of disease.' 3 But it
was a strange experiment, because it was not conducted in one of Pasteur's lab-
oratories. It was conducted on a farm, observed by reporters and crowds of Pa-
risians. It was also not on Pasteur's normal experimental agenda, for it had re-
sulted from a challenge by other eminent medical experts. The intensity of the
"Cavalieri, supra note 38, at I 155-56.
Ilid. at 1155.
"lid. at 1155.
'
21d. at 1156.
143DE KRUIF. supra note 137, at 150-54.
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scientific debate between Pasteur and his opponents had gotten so high that
Pasteur exchanged insults at one meeting with a Dr. Jules Guerin, resulting in
a near fistfight and a challenge to a duel.'" But the vaccine test was a success
and it got Pasteur worldwide headlines as "an unprecedented success."
But the height of success may not have prepared Pasteur for what was to
come. A year later, because thousands of sheep had died of anthrax contracted
from Pasteur's vaccines, angry farmers sent Pasteur letters. Robert Koch, con-
ducting clinical tests with Pasteur's vaccine, found that some batches of the
vaccine killed sheep.'"5
In a letter Koch sent to Pasteur, Koch chided Pasteur for his showman-
like passion for science and the truth, a passion which, Koch observed, did not
go so far as to allow for the revelation of Pasteur's unsuccessful results. Also,
in a finishing remark, as appropriate now as it was then, Koch admonished
Pasteur: "Such goings-on are perhaps suitable for the advertising of a business
house, but science should reject them vigorously. . .. "I'
Koch himself would later stumble over a prematurely disclosed report of
his experiments with tuberculosis. Koch would announce the discovery of the
tubercle bacillus in March 1882,"17 but a cure was a good deal of work away. In
1885, Koch was made head of the Hygienic Institute in Berlin. It was while at
that position in 1890 that Koch discovered the injection of a substance he called
tuberculin, the solution of heat-killed tubercle bacteria which seemed to arrest
tuberculosis in test animals.'" It was at a conference in 1890 that Koch made a
tragic gaffe. Partly as a result of pressure from the German government, Koch
decided to announce his preliminary findings. The Minister of Culture em-
phasized the new discovery in his introduction. Because Koch's injections
could kill tubercle bacilli, the minister implied a cure. Koch only served to rein-
force that inference with one sentence, stating that tuberculin had proved able
to check the growth of the tubercle bacillis, not only in test tubes, but also in
living animals. However, the animals were only guinea pigs and Koch's ex-
periments were not over. Unfortunately, the transatlantic cable carried the
news to America and presses rolled."9
Patients at the Saranac Lake, N.Y. sanitarium traveled to New York City
to obtain some of the new drug as soon as it would arrive from Europe. Unfor-
tunately, tuberculin turned out not to be a cure. Because doctors overdosed pa-
tients, some patients died.'"
'"Id. at 147.
"I1d. at 157-58.
'"Id. at 159.
"'D.C. KNIGHT. ROBERT Ko.H - FATHER OF BACTERIOLOGY. 88-90 (1%1).
'Old at 106-07.
1"Id. at 108-10.
'I'ld. at I I 1-12; See also A.L. BARON. MAN AGAINST GERMS. 61-64 (11957).
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The debacle which followed Koch's announcement cannot be blamed en-
tirely on Koch, for the press played up what they wanted to hear. But there are
other indications that the research community was infected with the spirits of
Barnum and Bailey. Dr. Max Pettenkofer, after making a public speech vow-
ing to "look death quietly in the face" and "die in the service of science as a
soldier perishes on the field of honor," on October 7, 1892, deliberately
swallowed a broth culture of comma-shaped cholera bacteria. Pettenkofer, not
an opponent to the germ theory, nevertheless did not feel the bacteria isolated
was the cause of cholera. Surprisingly, Pettenkofer did not die, he developed
only mild flu-like symptoms, which apparently encouraged Pettenkofer's assis-
tant to repeat the experiment with more drastic, but still not fatal results.'
Still later in 1892, another researcher, Elie Metchnikoff, repeated the same ex-
periment on himself and three of his assistants. One of the assistants developed
a near-fatal infection; another recovered but died shortly after from unknown
causes."' Metchnikoff developed the theory of white-blood cells engulfing in-
vading bacteria, but he had also accepted a position at the Pasteur Institute
shortly after one of his anthrax vaccines had killed a few thousand sheep.'53
Still another researcher, a student of Robert Koch's, rubbed test tubes of staph
on his arms, developing a serious case of boils, "proof," he said, that the staph
was the cause of boils and carbuncles.'54 The question which needs to be asked
is whether some of those researchers were interested in proving a theory or
simply interested in grabbing early headlines with a more dramatic form of
proof, though not a more scientific one.
In the March 31, 1980, issue of Time magazine, the cover story featured a
newly synthesized drug called interferon. Within the article was an illustration
similar to a Paul Revere rider, riding from one cell to another to warn of an im-
pending viral attack.' It was felt by many of the scientists interviewed that in-
terferon showed early promise as a cancer fighter. It would later be discovered
that interferon works not like a warning rider, but instead, like a giant freezer
or ray-gun. Instead of initiating an active defense by the cell, interferon ap-
pears to temporarily stop the cell's own functions, preventing a virus from
utilizing those functions to take over the cell. During large-scale testing of in-
terferon in 1982, four French cancer patients died and the French government
suspended further testing.'
... AND THE BISHOPS OF ASILOMAR
One of the shortest, but most flamboyant attacks on the proceedings at
"'A. CHASE. supra note 131, at 153-54.
" id. at 155.
"'DE KRUIF, supra note 137, at 207.
114d. at 132.
'"Time, Interferon. The Big IF in Cancer. March 31, 1980 at 62.
"1'E.J. SYLVESTER & L.C. KLOTZ. THE GENE AGE - GENETIC ENGINEERING AND THE NEXT INDUSTRIAL
REVOLUTION. 10 (1983) [hereinafter cited as SYLVESTER).
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Asilomar was voiced by microbiologist Erwin Chargaff. In what has become a
classic quote in rDNA literature, Chargaff likened Asilomar to the high coun-
cils of the Church by stating, "[alt this Council of Asilomar there congregated
the molecular bishops and church fathers from all over the world, in order to
condemn the heresies of which they themselves had been the first and principal
perpetrators.''5 7
At the Tuesday session of Asilomar, James Watson observed that "[tihese
people have made up guidelines that don't apply to their own experiments."''5
The comment succinctly states one of the stronger criticisms which can be lev-
eled at both Asilomar and the later scientific meetings, namely that the level of
risk and the corresponding degree of control on experimentation were as-
signed, not on the basis of hard empirical data, but on an almost ad hoc or arbi-
trary basis. It was as if to say - "but how can that work be dangerous, Dr.
Smith is working with that." James Watson asked point blank why frog DNA
was considered safer than cow DNA - and received no answer. 9 Also an ob-
server of still another subsequent meeting wondered whether guidelines
weren't "tailored to fit particular experiments that are already on the drawing
boards. ' ' "w
A more general criticism which can be applied to Asilomar and subse-
quent proceedings is that what began as a sincere interest in safety was slowly
turned into a legalistic and somewhat transparent shield, useful in the on-going
fight against government regulation. Asilomar, it would be argued, was proof
positive that the scientific community could regulate itself. From what trans-
pired at the conference, it becomes apparent that the motivation for self-reg-
ulation was not always the fear that human tragedy might result from exper-
imentation. Instead, a prime mover for self-regulation was the fear of and con-
tempt for government involvement. 6' To the extent NIH involvement was
sought, it was an attempt to forestall a still deeper and more extensive govern-
ment involvement. Therefore, the prospect of NIH involvement on the level of
partner was preferable to the prospect of Congressional involvement as
overseer.
LESSONS FROM GALILEO
Defenders of academic freedom, in using Galileo's image, have drawn on-
ly one lesson from the Inquisition's proceedings. In perspective, Galileo
escaped with a relatively light sentence. It must be remembered that earlier
popes had few qualms about launching the Crusades, which involved
"Chargaff, A Slap at the Bishops of Asilomar, 190 Sd. 135 (1975).
"'ROGERS, supra note 4 at 75.
"'Id. at 75.
16Wade, Recombinant DNA: NIH Sets Strict Rules to Launch New Technology, 190 Scl. 1175, 1179
(1975).
"'See ROGERS, supra note 4, at 62, 76, 78.
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thousands of deaths and that the Church, when faced with smaller but more
direct threats, did not hesitate to dispatch, with equal ferocity, what it con-
sidered heretical challenges to its authority.
What the Church perhaps feared the most from Galileo was having to go
back and decide already settled questions of doctrine on a case by case basis.
Once an already established assumption was successfully challenged, a lot of
cases could then be brought up for reexamination.
Expediency may answer the reverse side of such an argument. Why was
Galileo, one of the day's leading thinkers, so easily sacrificed to the preserva-
tion of a philosophical worldview which, in reality, was nothing more than a
bureaucratic convenience. A monk in some far-off northern country, by the
suppression of Galileo's thought, was saved the embarrassment of having to re-
think, reevaluate, and ultimately defend some illogical aspects of Church doc-
trine.
Before we rush to condemn the medieval Church as a haven for dogmatic,
but misguided zealots, it might be well to remember that we have incorporated
and presently utilize similar, if not identical methods and systems of thought.
We too, have areas in which we find it expedient to leave well enough alone;
areas which we do not wish to continually examine on a case by case basis. A
prime example is found in the rDNA debate itself. For all the intensity of the
debate, few, in fact no scientists, have dared to question the academic creden-
tials of scientists on the other side. In fact, society as a whole does not easily
permit such challenges. Doctors or lawyers who have successfully gained ad-
mission to a profession by passing the necessary exams are deemed qualified to
practice it. A similar example is found in the legal area. While an occasional in-
nocent person is found guilty of a crime, appeals courts have found it expe-
dient to leave the decisions of trial courts alone. While this can be criticized as
providing a convenient out for the judicial system, any other course would
leave individuals in a state of uncertainty for years, and would slowly bring
society to a chaotic but certain standstill.
It is a distinct advantage to be able to place a cherished belief in the class
or on the level of an established presumption. What happens when beliefs,
cosmologies, or concepts of nature become sanctified or elevated into iron-clad
or universal truths or universal principles of nature? 2 They become immune
from challenge. Therefore, their proponents must no longer lay a foundation
for their actions and it becomes quite easy to move ahead.
It is possible to argue that what happened at Asilomar and what resulted
was an attempt by the scientific community to place its profession and its ac-
tivities on a high plane. A plane from which such activities would be immune
from any challenges from below. Asilomar was to set an example, to prove
"'See J. RIFKIN, ALGENY, 20-41 (1984).
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that the biomedical research community was unique among the professional
organizations because the group possessed sufficient moral stamina to regulate
itself. Asilomar was to be offered as proof absolute that there was at least one
unique group whose moral standing was beyond reproach, whose pro-
nouncements would be an unchallenged assumption, and whose activities
would be beyond question. Asilomar was such an attempt. And while it can be
argued that it was a success, it can as easily be argued that it was a failure.
Scientists certainly can make the argument that Asilomar was proof of
the ability to self-regulate, just as they can assert that they are in danger of
persecution from some twentieth century Inquisition. Whatever assertions
scientists may make, the assertion that they, as a group, possess a superior
moral authority, a greater intelligence, or a physical dexterity sufficient to
carefully control dangerous organisms, simply does not accord with the facts.
Beginning with the legal side, scientists made a fundamental error. It is
such a gross mistake that if called before a jury they would be found liable
without doubt. They assumed that they could focus solely on the best aspects
of an activity, without so much as giving a thought to the worst. They as-
sumed that when the "best and brightest" are at their best, danger from the
stupid has simply vanished. A fundamental tenet of the law of tort is that the
best and brightest must not only be intelligent enough to eliminate their own
mistakes, but must also be able to anticipate and prevent the mistakes, stupidi-
ty, and carelessness of others. The president of a grocery store chain is never
called to testify on the question of whether he or she would be stupid enough
or careless enough to leave a banana peel lying on the floor.
It would not be enough for the Asilomar participants to establish their
own conduct or care. To support their argument they would have to account
for the activities of all scientists, past, present and future. From the small
sampling of past medical disasters already cited, their argument would be
rather weak. Even putting aside as insane the conduct of the German medical
corps during World War II, where German doctors transplanted human bones
and organs and injected gangrene, tetanus or staph bacteria into human sub-
jects,'63 the Asilomar participants have a heavy burden to carry.
On the experimental side, the mistakes of Pasteur and Koch are less ex-
treme than one or two other quite bizarre examples. H.T. Ricketts became
famous for his studies into deficiency diseases. In 1917 he was studying the
transmission of typhus by lice. He made the unfortunate and fatal mistake, not
only of collecting lice in an envelope, but also of carrying the unsealed
envelope in his pocket - from which the lice escaped and infected him.'" A
"
3V. LASKA. ed., WOMEN IN THE RESISTANCE AND IN THE HOLOCAUST. THE VOICES OF EYEWITNESSES.
(1983). See Accounts of Doctors Treite, Karl Gebhardt, Ernst Fischer, and Josef Mengele at 35, 219-20, and
225-26.
'"SYLVESTER, supra note 156 at 143.
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plumber working at Fort Detrick, the Army's biological warfare research
center, contracted a fatal case of anthrax when he entered an area posted with
a sign reading "DO NOT ENTER WITH OPEN WOUND." The plumber had
recently had a tooth pulled.'65
Perhaps the most unsettling incident was one which occurred just two
years prior to Asilomar. It is unsettling for two reasons; first, the relaxation of
safety precautions rested on the assumption that modern immunization had
eliminated risks to the population from the disease and second, although doc-
tors knew of the place where the disease was contracted, they did not diagnose
it until a week after it had run its course. The disease was smallpox. It must
have been a close relation to the epidemic pox which decimated the Aztec
population, for like that earlier version the 1973 disease proved fatal to a
young couple.
The virus initially infected a laboratory worker who happened to be in a
room where smallpox was being harvested from half-open eggs on an open
laboratory bench. When the disease manifested itself two weeks later it was
first thought to be influenza, which diagnosis was later changed to possible
meningitis, then to an antibiotic reaction, next a possible fungal infection, and
finally a glandular fever. Not until a week after release was the lab worker's
case recognized as smallpox. By that time the disease had been passed on to a
young couple and within several weeks, both individuals had died. Public
health officials had one body cremated, the other sealed in a disinfectant-
saturated coffin and buried by gravediggers given fresh vaccinations."
If researchers were to assert the argument that Asilomar proved, if not the
experimental, at least the moral superiority of their calling, they might have
difficulties once more in squaring their argument with the facts. To begin with,
James Watson's book, The Double Helix'61 provides one strike against them on
that score.
The Double Helix is nothing, if not interesting. But it does illustrate, on a
lighter level, some of the excesses which the intense competition in research
can bring out. Nobel prize winner Linus Pauling somehow inherited Louis
Pasteur's flair for the dramatic and, as the book states, Pauling was resented
for that trait. 68 That resentment is not one of the excesses. The excesses one
might point to are a failure to inform Pauling of a mistake in one of his papers
and a refusal to share pictures and information with Pauling. 69 Two aspects of
The Double Helix are unsettling. The first is that Pauling even made a mistake
and that the mistake was in elementary college chemistry. The second unsettl-
"'6ROGERS. supra note 4 at 125.
' Id. at 107-09.
1'J.D. WATSON. The Double Hefix. (1969).
'Id. at 30.
'Id. at 104. 107-08.
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ing aspect is that Watson and his colleagues were not particularly anxious to
reveal that error to Pauling, just as they were not particularly eager to share
some x-ray pictures which might help him.
The events described in The Double Helix provide a comic note since no
lives were at stake in the contest; the theoretical side of a subject providing
that type of leeway. More serious are the fights in applied science, where a
refusal to share information or to cooperate can affect the course of research
and ultimately the course of disease. What came out of Asilomar and subse-
quent proceedings reveals some shortcomings on the moral side of research.
More serious is the inability of the NIH to account for its actions in the inten-
tional release area.
One story, which came out at Asilomar, concerns a researcher named An-
drew Lewis. In 1971 Lewis was associated with the Laboratory of Viral Dis-
eases at the National Institute of Allergy and Infectious Disease (NIAID). As
Lewis described his experiences on a Tuesday afternoon at Asilomar, his audi-
ence of scientists listened in what turned into a hostile silence. In the course of
Lewis' work at NIAID, five strains of SV40 hybrids, with an unknown hazard
level, were identified and entrusted to Lewis for distribution. Worried that dis-
tribution was not safe, Lewis had hesitated to send out cultures, until the
strains were described at the Cold Spring Harbor Tumor Virus Workshop held
in August 1971. If Lewis didn't distribute the viruses, there would, it was
hinted, be congressional action, administrative pressure from NIH, and a letter
to Science. Lewis, forced to act, felt that he should at least require some formal
promise of safety in return for receiving the virus. But his Memorandum of
Understanding, Lewis' prerequisite to distribution, requiring the assumption of
full moral and legal responsibility, was not well received. As he told the at-
tendees at Asilomar, several major laboratories would not support the mem-
orandum, and more ominously, one or more of the laboratories seem to have
ignored Lewis' request that the original virus hybrid cease to be distributed. 7
The reasons for the hostility toward government regulation result in part
from personal experience by researchers with the paperwork and bureaucratic
politics involved in research. One researcher probably spoke for many when he
told Michael Rogers that "[already we spend two months a year applying for
grants; now we're afraid we'll spend another month filling out more forms.
And the forms don't protect anybody; they just take more time."''
To assume something, is by one definition, to take for granted something
that is not proved. In stating that forms don't protect anyone, the researcher
stated an apparently widespread belief among those at Asilomar. But it is only
assumption and it is further evidence that scientists, who are supposed to make
" ROGERS. supra note 4, at 69-71.
"'Id. at 83.
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statements based only on experimentation and testing, make that advice more
the exception than the rule. The assumption relating to paperwork is a false
one.
The deaths which resulted from Koch's premature announcement of ex-
perimental results with tuberculin occurred because there was no watchdog
organization to require experimental proof on paper. Dr. Edward Trudeau, at
the time of Koch's announcement, had been only partially successful in pro-
tecting guinea pigs against tuberculosis.' Pasteur's disappointments with his
anthrax vaccine resulted, not so much from theoretical errors, but from the
practice of attempting to mass-produce vaccine in his experimental laboratory
rather than a factory.73
Perhaps some of that detested paperwork might have curtailed the
damage done by therapeutic radiation use by the medical profession during the
period from the late 1930s to the early 1960s. However the practice got
started, it is testimony to the fact that the medical profession is as prone to rely
on a tradition, once established, as it is to resort to empirical evidence. Radia-
tion therapy was well accepted medical practice, prescribed to shrink tonsils
and adenoids or to treat acne, fungal infection and dermatitis.'74 Although
reports on the correlation between radiation and cancer began circulating as
early as 1950, the practice continued for another ten years. 75
Just how important paperwork and regulation can be is most strongly
presented by the actions surrounding the attempt by the William S. Merrell
Co. to introduce the drug thalidomide into the United States.'76 It is at once the
most damning and conclusive proof that whatever high ideals Asilomar may
have represented, such ideals and efforts are insufficient to overcome the real
shortcomings of the research community and the very real dangers those short-
comings present to society. Because an administrative agency, the FDA, re-
quired paperwork, thalidomide did not become a greater American tragedy.
On September 12, 1960, the William S. Merrell Company submitted a
New Drug Application (NDA) to the FDA, which assigned the NDA for re-
view to Dr. Frances Oldham Kelsey, the newest medical officer on the FDA
staff.'77 The review should have been a routine one. Superficially, the drug had
every appearance of being safe, having been test marketed in West Germany
"'KNIGHT. supra note 147 at I I1.
"3DE KRUIF. supra note 137, at 155-56.
"4See Management of Patients with a History of Radiation Therapy to the Head and Neck During
Childhood 77 J. KANS MED. Doc. 212 (1976); Continuing Occurrence of Thyroid Carcinoma After Irradia-
tion to the Neck in Infancy and Childhood. 292 NEw ENG. J. MED. 171-73 (1975).
"'See B.J. Duffy, P.J. Fitzgerald, Cancer of the Thyroid in Children: A Report of 28 Cases, 10 J. CLIN. EN-
DOCRIN. & METAB. 1296 (1950); A.C. Schultz, M.D., Childhood Irradiation and the Incidence of Thyroid
Cancer, 63 MINN. MED. 535-38 (July 1980).
'McFadyen, Thalidomide in America: A Brush with Tragedy. II CLIO MED. (2) 79-93 (July 1976).
'"Id. at 80.
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as early as November 1956.7 But Dr. Kelsey felt that Merrell's evidence, sub-
mitted to establish the drug's safety, was inadequate. The supporting clinical
reports sounded more like testimonials than scientific studies."9 Dr. Kelsey
drafted a letter to Merrell stating that chronic toxicity data was incomplete
and no evaluation could be made. The letter served to delay approval for a
60-day period. 8
Merrell seemed, nevertheless, intent on getting the drug marketed. In
what was described as one of the most "severe" applications of pressure, Mer-
rell's representatives repeatedly made phone calls and personal visits in an ef-
fort to gain approval for the drug.'
In an issue of the British Medical Journal read by Dr. Kelsey in February
1961, there was a report of possible side effects from thalidomide involving de-
terioration of nerves in the hands and feet.'82 Merrell's medical staff felt the re-
port was of no major consequence. After European meetings with English and
German representatives for drug manufacturers, Merrell's staff assured the
FDA that the incidence of side-effects was low and rapidly reversible. Merrell
representatives suggested that any such toxic side-effects could be taken care
of with a warning label."' But proof of the drug's safety was never forthcom-
ing. Stressing the lack of actual proof that thalidomide caused nerve deteriora-
tion, Merrell attempted to throw the burden of proof on the government."
In an attempt to gain approval for the 1961 Christmas market, in
September Merrell brought in clinical investigators to talk to the FDA. Never-
theless, FDA officials remained unconvinced that Merrell had proved the safe-
ty of the drug. On November 30, 1961, Dr. Kelsey was informed by telephone
that thalidomide had been withdrawn from the German market. Congenital
abnormalities during pregnancy were reportedly now linked to the drug.
Ironically, it was the Merrell official who had exerted pressure on Dr. Kelsey
for approval of the drug, who telephoned Dr. Kelsey with the information.'85
The telephone call to Dr. Kelsey was not the end of the story. The FDA
assumed that Merrell had intended to use a limited number of clinical investi-
gators, some thirty-five to sixty. Yet when the FDA in April 1962 requested
that Merrell provide information on steps being taken to warn physicians of
the dangers, it learned that Merrell had sent the drug to over one thousand
doctors."' On July 20, 1962, an executive vice-president of Merrell met with
"'Id at 79.
1'91d. at 80.
"Id. at 80-81.
1111d.
111d. at 81.
1i3 Id.
'id. at 82.
1831d.
"Id. at 84.
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the commissioner of the FDA and assured him that a recall of the drug had
been completed and that all clinical investigators had been contacted by phone,
wire, or in person. Yet, when an FDA inspector visited Merrell's offices on July
23 and 24, Merrell was still in the process of contacting the 1,126 physicians
who had received the drug. In addition, while some 5 tons of thalidomide had
been returned to Merrell, over two tons remained unaccounted for.'87
An FDA survey showed that more than two million five hundred thou-
sand tablets had been distributed and given to almost twenty thousand pa-
tients. Some 624 of the twenty thousand were reported as pregnant.'88 West
German figures show that, in all, there were four thousand cases of birth
defects attributed to the use of the drug."s9
Central to the rDNA debate is the fact that a pharmaceutical company,
presumably an adherent to the same professional and ethical code as the
researchers at Asilomar, chose to rely on the appearance of safety provided by
the German field tests, rather than resorting to rigorous clinical testing of its
own. While it might be convenient to concede that in this one instance govern-
ment regulations actually worked, to imply, by the reverse argument, that in
most cases they don't work and are unnecessary, is a false and potentially
dangerous assumption. In fact, they work all the time. Newspaper stories giv-
ing accounts of real tragedies, the exception rather than the rule, should serve
as proof. Researchers, perhaps obsessed with the need for dramatic an-
nouncements, should not take their argument to its final conclusion, by requir-
ing tragic headlines to convince themselves of the need for stringent controls
on any undertaking.
Perhaps the most striking fallacy held by the participants of Asilomar was
that freedom from societal controls could be purchased for the price of a
meeting. Society imposes the greatest controls where it finds the greatest
danger, not where it finds the greatest virtue. Assuming that good intentions
are sufficient to avoid danger is like the story of the frog who reluctantly
agreed to carry a scorpion across a waterway after exacting a promise from the
scorpion that he would not sting him. Halfway across, the scorpion stung, and
as the frog began to sink, the scorpion was asked why he had stung the frog,
for now he would himself drown in the water. "Because," said the scorpion,
"it's in my nature." Viruses and bacteria are dangerous, regardless of the good
intentions of the researcher.
Asilomar was rDNA's answer to Pasteur's crowd-pleasing "scientific ex-
periment" with the anthrax vaccine. It was good public relations, but it fell far
"'Id. at 85.
'Old. at 86.
'"Bennett, D.M.J., The Liability of the Manufacturers of Thalidomide to the Affected Children, 39 THE
AUSTRALIAN L.J. 256, 266 (1965) (citing Taussig, A Study of the German Outbreak ofPhocomelia, 180 J. OF
THE A.M.A. 82 (1962)).
Summer, 19851
43
Barkstrom: The Regulation of Biotechnology
Published by IdeaExchange@UAkron, 1986
short of scientific proof. Pasteur at least provided the trappings of a genuine
experiment. Yet, while Asilomar provided good press, it lacked even the
semblance of reality which Pasteur's anthrax cultures provided. For while
Pasteur gambled his reputation against the hard evidence provided by animals
that anthrax kills, scientists at Asilomar lifted a year-and-a-half moratorium,
on nothing more than the speculative conclusions provided by what amounted
to a four-day philosophizing session.
Disease hazards run the gamit from the mild discomfort of colds to the
deadly symptoms of rabies. It is pure delusion to assume that Asilomar could
be offered as proof against all danger from the deadliest microbes. For to
eliminate the need for regulation, scientists would have to rule their domain so
tightly that, like the Biblical falling sparrow, they could hear a test tube break
in the most remote laboratory. The irony of the field in which they work is that
in order to bring any credibility at all to their argument, they could only buy
their freedom from regulation by a dictatorial control so extensive that govern-
ment regulation would seem like a summer breeze in comparison to a hur-
ricane. Asilomar proved only that scientists didn't wish to be regulated, it did
not prove that they should be free of regulation.
THE PRINCIPLE UNQUESTIONED
There are sound reasons why, like every other societal group, the research
community cannot be entrusted with any unquestioned privileges. First, even
some of its best, like Koch, Pasteur, and Ricketts have committed the rather
ordinary sins of being careless and possessing pride. Second, society is incapa-
ble, at times, of separating the true scientists from the snake-oil salesmen mas-
querading as true scientists. It is naive of some in the scientific community to
expect the rest of us to run for cover, to grant unrestricted freedom, simply be-
cause we are afraid of being likened to the Grand Inquisitor. On the financial
and budgetary side alone, we would be labeled as fools to simply grant carte
blanche to anyone requesting funds for medical research. Not to impose re-
strictions to prevent cheating is as unfair to those conducting needed research
as it is irritating to those who must submit their department to an audit."9
One might begin to suspect that what researchers cannot attain on the
basis of moral authority, they would nevertheless like to attain on some other
basis. The argument goes as follows: Even if research on a practical level is not
unique in terms of nobility, it is still unique in terms of value and technical dif-
ficulty, and on that basis, should be granted an exemption from the case by
case analysis applied to the endeavors of other groups.
What makes scientists uncomfortable is a comparison between their ideals
'"The Rocky Mountain News reported a UPI story concerning a Defense Department report that military
doctors may have pocketed or given assistants $47,000 in research money provided by drug companies and
research institutions. The Rocky Mountain News, Jan. 17, 1985, at 39.
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and expectations and their true actions. They do not like to be reminded that
while they preach academic freedom of inquiry and the open exchange of
ideas, their business interests and the need for secrecy in the genetic engineer-
ing field have placed them at odds with those very ideals.' 9' And while they will
bristle at the suggestion of any control being imposed on the areas they wish to
research, there is a growing tendency, on their own initiative, to forego
research in one area because another area may be of greater interest to in-
dustry.' Censorship by neglect is, after all, not forbidden by canons of ethics.
But the desire to be accorded the status and privileges which come with
the coronation of a principle is strong. Being accorded the privileges, without
the moral authority, still runs a strong second. The biomedical community, it
may be argued, was still unique, even if not morally superior. A participant of
Asilomar would be first to agree that biomedical researchers were among the
first groups in history to succeed in self-imposing a moratorium. And
biomedical researchers would like to believe that their field is not easily
understood by the layman' and that, whatever their faults, they are still
among a diminishing number of groups whose goals are the service of
mankind. Still another argument has made its appearance - an "I told you
so," in the form of the assertion that the money spent on debate and regulation
was simply a waste and could have been better spent on research.'94 That may
be so, but those who assert such an argument may not want it taken to its
logical conclusion. If that were to happen researchers might have to begin ex-
plaining to auditors on a yearly basis why funds were "wasted" on a project
which did not result in a cure for cancer.
Repeated references to Galileo may, in the end, do more harm than good.
Such references only serve as a reminder that the scientific community can it-
self play the role of Grand Inquisitor as often as it enjoys the role of Galileo.
The scientific threats aimed at Andrew Lewis, to compel him to distribute his
viruses, the pressure placed on the FDA to approve thalidomide, and even the
milder forms of intimidation applied to those who opposed rDNA work,' 9"
hardly comport with analogies to the broken man forced to recant before the
inquisitors.
CONCLUSION
Whether the dangers from rDNA research are actually behind us remains
to be seen. It may be that those questions involving the purely ethical areas
may loom larger in the future than those from the technical side ever actually
"'SYLVESTER. supra note 156, at 134-35.
'"Id. at 134.
93ROGERS, supra note 4, at 76, 78.
'"See Tooze, International and European Regulation of Recombinant DNA Research, 12 U. TOL. L. REV.
869, 889 (1981); B.R. Levin, Changing Views of the Hazards of Recombinant DNA Manipulation and the
Regulation of These Procedures, 7 Recombinant DNA Technical Bulletin, No. 3, 107, 112 (Sept. 1984).
'"ROGERS. supra note 4 at 187-89.
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do.
In 1945, scientists working on the Manhattan Project speculated that the
detonation of a nuclear device in the atmosphere might generate such intense
heat that it would start a chain reaction involving the entire earth's at-
mospheric oxygen, destroying the planet. They were quite relieved when no
such chain reaction occurred on the detonation of the bomb at Alamogordo,
New Mexico, proving the theory an imaginary one. They might not have been
so quick to relax had it been realized that within forty years of that first explo-
sion, the Doomsday Clock, a rough estimate of the world's nuclear arsenal,
would be hovering between five and two minutes to midnight. Whether there
are hidden dangers in biological research will only become apparent at some
future date.
It should be apparent, however, that while we may keep a wary eye on the
future, that future should not blind us to our past. As scientists, researchers
would do well to focus on where empirical evidence leads, not on where they
want it to take them, while ignoring standard procedures in favor of short-term
goals, which has often proved a formula for disaster. So too, in the legal area,
attempts to restructure long-standing safeguards to fit present goals has often
proved no formula for success.
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